

4TH World Congress of Cutaneous Lymphomas

12-14 February, 2020

www.wcclbarcelona2020.com

4WCCL

BAR
CE
LO
NA

FINAL PROGRAM



DEAR FRIENDS AND COLLEAGUES,

On behalf of the 4th World Congress of Cutaneous Lymphomas (WCCL) Organizing Committee and the International Society for Cutaneous Lymphomas (ISCL) it is a great pleasure to welcome you to the 4th WCCL Congress in Barcelona, Spain on February 12-14, 2020!

Following three highly successful Congresses in Chicago 2010, Berlin 2013, and New York 2016, the 4th World Congress in Barcelona presents a wonderful opportunity to share experiences, to exchange scientific ideas, and foster interactions between physicians, researchers, and all involved in the field of cutaneous lymphomas. The program provides an innovative and comprehensive overview of the state-of-the-art advances in basic, translational and clinical research; it discusses new developments in the diagnosis, practice and management of cutaneous lymphomas, promoting the highest standards of care and support of the patients.

The 4th WCCL provides a premier interdisciplinary platform for all participants (basic scientists, dermatologists, hematologists, clinical oncologists, dermatopathologists, radiation oncologists, and others) not only to share the updates and the most recent advances, but also discuss practical challenges in the field of cutaneous lymphomas.

Barcelona is a magnificent and beautiful cosmopolitan city, a perfect setting for the congress thanks to its privileged position in the Mediterranean shore, gateway and home of several ancient cultures that has always represented the essence of art, culture and progress.

Welcome to the 4th WCCL in Barcelona!



Dr. Larisa Geskin
Co-Chair of the 4WCCL 2020



Dr. Ramón M. Pujol
Co-Chair of the 4WCCL 2020

JOIN THE ISCL!

We encourage you to join the International Society for Cutaneous Lymphomas, the organizing society of the World Congress of Cutaneous Lymphomas. The ISCL is dedicated to the treatment, research, and caring of patients with cutaneous lymphomas. The ISCL was founded in 1992 at the World Congress of Dermatology in New York and among its aims are to increase knowledge of lymphoproliferative and related disorders of the skin, foster collaboration among clinicians and scientists, and promote dissemination of scientific information.

To apply for membership, please complete the application form at the following link: www.cutaneouslymphoma.org



World Congress of Cutaneous Lymphomas

TABLE OF CONTENTS

Contacts	4
Guest Lectures	5
Faculty	6
Acknowledgements and Exhibitors	7
Scientific Program	
> Program at a glance	8
> Wednesday, 12 th February 2020	11
> Thursday, 13 th February 2020	14
> Friday, 14 th February 2020	20
Posters sessions	24
Industry Satellite Symposiums	29
Guidelines for authors	30
General Information	31
Authors Index	33

SCIENTIFIC PLANNING COMMITTEE

- > Ramón M. Pujol, Co-Chair | Spain
- > Larisa Geskin, Co-Chair | USA
- > Martine Bagot | France
- > Francine Foss | USA
- > Joan Guitart | USA
- > Emmilia Hodak | Israel
- > Chris McCormack | Australia
- > José Antonio Sanches | Brazil
- > Julia Scarisbrick | U.K.
- > Makoto Sugaya | Japan

LOCAL ORGANIZING COMMITTEE

- > Ramón M. Pujol
- > Fernando Gallardo
- > Teresa Estrach
- > Octavio Servitje
- > Pablo Ortiz Romero
- > Ricardo Fernández de Misa

4WCCL WORK GROUP

- > Ramón M. Pujol, Co-Chair
- > Larisa Geskin, Co-Chair
- > Fernando Gallardo
- > Joan Guitart
- > Emmilia Hodak
- > Julia Scarisbrick
- > Victoria Ceh, ISCL Executive Director
- > Melanie Stancampiano, ISCL Program Manager
- > Maria Sanmiguel, Congress Secretariat/Grupo Pacífico

ISCL BOARD OF DIRECTORS

PRESIDENT: Larisa Geskin, MD | USA
SECRETARY: Emmilia Hodak, MD | Israel
TREASURER: Julia Scarisbrick, MBChB, MD | U.K.
IMM PAST PRESIDENT: Joan Guitart, MD | USA

- > Martine Bagot, MD, PhD | France
- > Antonio Cozzio, MD, PhD | Switzerland
- > Jade Cury Martins, MD, PhD | Brazil
- > Paula A. Enz, MD | Argentina
- > Steven M. Horwitz, MD | USA
- > Michael Khodadoust, MD | USA
- > Ivan Litvinov, MD, PhD, FRCPL | Canada
- > Christopher McCormack, MBBS | Australia
- > Montserrat Molgo, MD | Chile
- > Pablo L. Ortiz-Romero, MD, PhD | Spain
- > Evangelia Papadavid, MD | Greece
- > Lauren C. Pinter-Brown, MD | USA
- > Ramon M. Pujol, MD, PhD | Spain
- > Christiane Querfeld, MD, PhD | USA
- > Alain H. Rook, MD | USA
- > Yoshiki Tokura, MD, PhD | Japan
- > Yang Wang, MD, PhD | China

FOUNDING MEMBER: Günter Burg, MD
FOUNDING MEMBER: Peter Heald, MD
FOUNDING MEMBER: Eric C. Vonderheid, MD

ISCL HEADQUARTERS

1932 S. Halsted St., Suite 413
Chicago, IL 60608 USA
+1-630-578-3991
EXECUTIVE DIRECTOR: Victoria Ceh, MPA
info@cutaneouslymphoma.org
cutaneouslymphoma.org/default.aspx

EORTC CUTANEOUS LYMPHOMA TASK FORCE

CHAIR: Julia Scarisbrick, MBChB, MD | U.K.
SECRETARY: Antonio Cozzio, MD, PhD | Switzerland
TREASURER: Evangelia Papadavid, MD | Greece

EORTC HEADQUARTERS

Avenue Emmanuel Mounier 83/11
1200 Brussels, Belgium
www.eortc.org/research_field/cutaneous-lymphoma/

UNITED STATES CUTANEOUS LYMPHOMA CONSORTIUM (USCLC) BOARD OF DIRECTORS

PRESIDENT: Francine Foss, MD
SECRETARY-TREASURER: Madeleine Duvic, MD
IMM PAST PRESIDENT: John Zic, MD

- > Wei Ai, MD
- > Oleg Akilov, MD, PhD
- > Joi Carter, MD
- > Larisa Geskin, MD
- > Michael Girardi, MD
- > Alejandro Gru, MD
- > Ellen Kim, MD
- > Stefan Schieke, MD
- > Jasmine Zain, MD

REGISTRY CHAIR: Elise Olsen, MD

USCLC HEADQUARTERS

6134 Poplar Bluff Circle, Suite 101
Norcross, GA 30092 USA
+1-770-613-0932
EXECUTIVE DIRECTOR: Alyson Conley
alyson@theassociationcompany.com
<http://www.usclc.org/>



ZACKHEIM LECTURE

The Herschel Zackheim Lectureship was established to honor Dr. Herschel Zackheim (1914-2009) a clinical professor emeritus at UCSF, who pioneered the discovery of treatments for patients with cutaneous lymphoma. The Lectureship recognizes and honors a clinician and/or researcher who has been a significant contributor to advancing the science and understanding of lymphoma-related biology, has contributed research that has or will be expected to improve treatment for lymphoma patients, and has outstanding leadership qualities.



Elías Campo, MD, PhD Hospital Clinic of the University of Barcelona, Spain

Doctor Elías Campo is the clinical director of the Biomedical Diagnostic Centre of Hospital Clínic and a full professor of Anatomical Pathology at the University of Barcelona, where he also teaches in the Department of Anatomical Pathology, Pharmacy and Microbiology. He is the Spanish coordinator of the International Cancer Genome Consortium.

Zackheim Lecture: Principle & practice or method for classifying lymphomas (how why when)
Wednesday, February 12th 2020
Auditori. 8:45-10:00h

PLENARY SESSION



Manel Esteller, MD, PhD Josep Carreras Leukemia Research Institute Barcelona, Spain

Director of the Josep Carreras Leukaemia Research Institute (IJC) in Badalona (Barcelona). He is also Chairman of Genetics at the School of Medicine of the University of Barcelona, and an ICREA Research Professor. His current research is devoted to the establishment of the epigenome and epitranscriptome maps for normal and transformed cells, the study of the interactions between epigenetic modifications and non-coding RNAs, and the development of new epigenetic drugs for cancer therapy.

Plenary session: Epigenetics in Lymphomagenesis: An Update and Examples for Cutaneous Lymphoma
Thursday, February 13th 2020.
Auditori. 9:00-9:30h



CHAIRS AND CO-CHAIRS:

- > Akilov O.
- > Assaf CH.
- > Bagot M.
- > Battistella M.
- > Berti E.
- > Beylot-Barry M.
- > Cerroni L.
- > Choi J.
- > Cozzio A.
- > Duvic M.
- > Enz P.
- > Estrach T.
- > Foss S.
- > Gallardo F.
- > Geskin L.
- > Girardi M.
- > Gniadecki R.
- > Gru A.
- > Guenova E.
- > Guitart J.
- > Hodak E.
- > Hoppe R.
- > Horwitz S.
- > Hwang S.
- > Junkins-Hopkins J.
- > Kempf W.
- > Khodadoust M.
- > Kim E.
- > Kim Y.
- > Klemke C.
- > Knobler R.
- > Koralov S.
- > Kupper T.
- > Litinov I.
- > Matsuoka M.
- > McCormack C.
- > Molgo M.
- > Musiek A.
- > Nicolay JP.
- > Nikbakht N.
- > Olsen E.
- > Ortiz-Romero P.
- > Papadavid E.
- > Pimpinelli N.
- > Pittelkow M.
- > Porcu P.
- > Prince H.
- > Pujol R. M.
- > Pulitzer M.
- > Quaglino P.
- > Querfeld C.
- > Rook A.
- > Rosen S.
- > Sanches J.
- > Scarisbrick J.
- > Servitje O.
- > Stadler R.
- > Stranzenbach R.
- > Sugaya M.
- > Trautinger F.
- > Vermeer M.
- > Wehkamp U.
- > Weng W.
- > Whittaker S.
- > Willemze R.
- > Wong H.
- > Zain J.
- > Zic J.

ACKNOWLEDGEMENTS AND EXHIBITORS

12-14 February, 2020

www.wccfbarcelona2020.com

GOLD SPONSOR

KYOWA KIRIN



SILVER SPONSOR

Adaptive
biotechnologies*

GALDERMA

HELSINN
Building quality cancer care together

innate pharma

Takeda


BRONZE SPONSOR

SOLIGENIX

BASIC SPONSOR

4SC

EXHIBITORS



In addition, we are grateful to the following companies for sponsoring:

- > **USB Sticks** - Innate Pharma

Wednesday 12 th Feb			
Time	Auditori - Plenary Room	Room 1	Room 2
7:00-7:15			
7:15-7:30			
7:30-7:45	Registration (Open all day)		
7:45-8:00			CLIC Steering Committee
8:00-8:15			
8:15-8:30			
8:30-8:45	Welcome Remarks		
8:45-9:00	Session A Classification of CL. Chair: J. Guitart. Co-chairs: R.Willemze, L.Cerroni,W.Kempf Zackheim Lecture: E. Campo		
9:00-9:15			
9:15-9:30			
9:30-9:45			
9:45-10:00	Session B Clinicopathological Correlation. Chair: E. Berti. Co-chairs: T.Estrach,		
10:00-10:15			
10:15-10:30			
10:30-10:45			
10:45-11:00	Coffee Break		
11:00-11:15			
11:15-11:30	Session C Prognostic Factors in CTCL. Chair: J. Scarisbrick Co-chairs: P.Porcu, P.Quaglino		
11:30-11:45			
11:45-12:00			
12:00-12:15	Lunch at NH Constanza Hotel		
12:15-12:30			
12:30-12:45			PROCLIPI Investigators Meeting (lunch box)
12:45-13:00			
13:00-13:15			
13:15-13:30			
13:30-13:45			
13:30-13:45	Session D Epidemiology. Chair: N.Pimpinelli Co-chairs: I.Litvinov, M.Pittelkov		
13:45-14:00			
14:00-14:15	Session E Immunology I: Chair: A.Rook Co-chairs: E.Guenova, O.Akilov		
14:15-14:30			
14:30-14:45			
14:45-15:00	Session F Immunology II: Chair: M.Girardi Co-chairs: N.Nikbakht, E.Papadavid		
15:00-15:15			
15:15-15:30			
15:30-15:45			
15:45-16:00	Coffee Break		
16:00-16:15			
16:15-16:30	HELSINN Symposium: Management of chlormethine gel-induced dermatitis: A case-based discussion. B. Poligone		
16:30-16:45	Session G Pathogenesis of CLs. Chair: M.Bagot Co-chairs: S.Koralov, L.Geskin		
16:45-17:00			
17:00-17:15			
17:15-17:30			
17:30-17:45			
17:45-18:00			
18:00-18:15			
18:15-18:30	18:20-Transfer departs		
	Welcome Reception at Palau de la Musica, visit and cocktail (19:00 - 21:30)		



Thursday 13 th Feb			
Time	Auditori - Plenary Room	Room 1	Room 2
7:00-7:15			ISCL BOD Meeting
7:15-7:30			
7:30-7:45	Registration (Open all day)		
7:45-8:00			
8:00-8:15	Session H	Session Z1	
8:15-8:30	Biomarkers I. Chair: M.Sugaya Co-Chairs: A.Gru, C.Klemke	Clinical Observations I. Chair: R.M. Pujol Co-chairs: J.Sanches, R. Stranzenbach	
8:30-8:45	Session I		
8:45-9:00	Biomarkers II. Chair: R. Stadler Co-chairs: U. Wehkamp, H. Wong		
9:00-9:15	Plenary Session: M. Esteller		
9:15-9:30	Chair: R.M. Pujol Epigenetics in Lymphomagenesis: An Update and Examples for Cutaneous Lymphoma		
9:30-9:45	Awards Ceremony		
	Chair: L. Geskin		
9:45-10:00	Coffee Break		
10:00-10:15	Session J	Session Z2	
10:15-10:30	Genetic Pathogenesis. Chair: M.Vermeer	Clinical Observations II. Chair: F.Foss Co-chairs: JP Nicolay, S.Rosen	
10:30-10:45	Co-chairs: J.Choi, R.Gniadecki		
10:45-11:00	Session K		
11:00-11:15	Epigenetic Abnormalities. Chair: T.Kupper		
11:15-11:30	Co-chairs: Ch.Assaf, M.Matsuoka		
11:30-11:45	Session L	Session Z3	
11:45-12:00	Genomic Insights. Chair: S.Whittaker	Clinical Observations III. Chair: E.Kim Co-chairs: A.Cozzio, P. Quaglino	
12:00-12:15			EORTC CLTF BOD Meeting
12:15-12:30			
12:30-12:45	Lunch at NH Constanza Hotel		
12:45-13:00			
13:00-13:15	USCLC General Meeting		
13:15-13:30			
13:30-13:45	Session M	Session Z4	
13:45-14:00	Molecular Characterization of Rare CLs I. Chair: M.Beylot-Barry	Clinical Observations IV. Chair: R. Kobler	
14:00-14:15	Co-chairs: J.Junkins-Hopkins, C. McCormack	Co-chairs: P.Porcu, P.Quaglino	
14:15-14:30	Session N		
14:30-14:45	Molecular Characterization of Rare CLs II. Chair: C.Querfeld Co-chairs: M.Pullitzer, M.Molgo		
14:45-15:00	Formal Poster Session I		
15:00-15:15	Even-numbered posters. Room Win. Level 0		
15:15-15:30	& Coffee Break		
15:30-15:45	KYOWA KIRIN Symposium: Clinical importance of assessing blood involvement in CTCL. M. Vermeer, S.L. Morris		
15:45-16:00			
16:00-16:15	Session O	Session P	
16:15-16:30	Cutaneous B-Cell Lymphomas. Chair: A.Cozzio	Quality of Life. Chair: A. Musiek Co-chairs: F.Gallardo, J.Zic	
16:30-16:45	Co-chairs: O.Servitje, M.Battistella		
16:45-17:00	Session Q		
17:00-17:15	Discussion & Controversies. Chair: E.Hodak		
17:15-17:30	Co-chairs: J.Guitart, R. Hoppe		
17:30-17:45	Discussions: E Hodak vs W Kempf, M Vermeer vs J Choi,		
17:45-18:00	S Horwitz vs H Prince		
18:00-18:15			
18:15-18:30			
	20:00-Transfer departs		
	Congress Dinner at La Llotja de Mar (20:30 - 23:30)		



Friday 14 th Feb				
Time	Auditori - Plenary Room	Room 1	Room 2	
7:00-7:15			USCLC BOD Meeting	
7:15-7:30				
7:30-7:45	Registration (Open all day)			
7:45-8:00				
8:00-8:15	Session R. Preclinical Development of Personalized Therapies I. Chair: L.Geskin Co-chairs: M.Khodadoust, S. Horwitz			
8:15-8:30				
8:30-8:45				
8:45-9:00				
9:00-9:15	Session S Preclinical Development of Personalized Therapies II. Chair: S.Hwang Co-chairs: W.Weng, F.Trautinger			
9:15-9:30				
9:30-9:45				
9:45-10:00				
10:00-10:15	Formal Poster Session II Odd-numbered posters Room Win Level O & Coffee Break			
10:15-10:30				
10:30-10:45				
10:45-11:00	Session T Novel Therapeutics. Chair: P. Porcu Co-chairs: M.Bagot, O.Akilov			
11:00-11:15				
11:15-11:30				
11:30-11:45	Session U Stem Cell Transplant. Chair: M.Duvic Co-chairs: J. Zain, H.Prince			
11:45-12:00				
12:00-12:15				
12:15-12:30	ISCL General Meeting			
12:30-12:45	Lunch Box at venue			
12:45-13:00				
13:00-13:15				
13:15-13:30	TAKEDA SYMPOSIUM: Current treatment patterns and targeted agents in the management of CTCL. P. Ortiz Romero, J. Scarisbrick			
13:30-13:45				
13:45-14:00				
14:00-14:15				
14:15-14:30	Session V Therapeutics I. Chair: Y.Kim Co-chairs: J. Zain, S.Horwitz			
14:30-14:45				
14:45-15:00				
15:00-15:15	Session W Therapeutics & Clinical Trials II. Chair: C.McCormack Co-chairs:E.Kim, P.Ortiz-Romero			
15:15-15:30				
15:30-15:45				
15:45-16:00	Coffee Break			
16:00-16:15	Session X Observations and Prospectives. Chair: E.Olsen Co-chairs: R. Knobler	Session Y Topical Chemotherapy. Chair: J. Sanches Co- chairs: M.Bagot, E.Hodak		
16:15-16:30				
16:30-16:45				
16:45-17:00				
17:00-17:15	Closing Remarks			



07:30 **Registration** (open all day)

07:30-08:30 **CLIC Steering Committee**
Room 2 at venue

08:30-08:40 **Welcome Remarks**

08:40-10:00 **Session A - Classification of CL: Past, Present, Future**

Chair: **J. Guitart** Co-Chairs: **R. Willemze, L. Cerroni, W. Kempf**

Zackheim Lecture: Principle & practice or method for classifying lymphomas (how why when). **E. Campo**

Debate Session: Classification of cutaneous lymphoma: what works and what doesn't

EORTC-WHO interaction and CBCL (12 minutes) / **R Willemze**

Debate (5 minutes)

Mycosis fungoides/Sezary syndrome and variants (10 minutes) / **L.Cerroni**

Debate (5 minutes)

CD30 lymphoproliferative conditions (10 minutes) / **W.Kempf**

Debate (5 minutes)

Cytotoxic lymphomas (10 minutes) / **J.Guitart**

Debate Closing (3 minutes)

10:00-10:50 **Session B - Clinicopathological Correlation**

Auditori 8 minutes

Chair: **E. Berti** Co-Chairs: **T. Estrach**

- B-01** Clinicopathologic correlation and short-term outcome analysis of a highly curated cohort of folliculotropic mycosis fungoides: an international virtual study
Emmilia Hodak / John Zic, International
- B-02** Folliculotropic Mycosis Fungoides – Results of an International Consensus Histopathologic Review
Alejandro Gru, International
- B-03** Plaque stage folliculotropic mycosis fungoides: histopathologic features and prognostic factors in a series of 40 patients
Suzanne Van Santen, Netherlands
- B-04** Adnexotropism: an under-recognized histopathological finding in aggressive cytotoxic cutaneous lymphomas
Christina J. Walker, United States
- B-05** Subcutaneous panniculitis-like T-cell Lymphoma (SPTCL): a large US case series reveals a lymphoma with limited growth potential in need of diagnostic and therapeutic guidelines
Joan Guitart, United States
- B-06** Granulomatous Mycosis Fungoides: a Clinicopathological Study of 41 Cases from a Tertiary Cancer Center
Carlos Torres-Cabala, United States

10:50 - 11:10 **Coffee Break & Poster Viewing**



11:10-12:00

Session C - Prognostic Factors in CTCL

Auditori 10 minutes

Chair: **J. Scarisbrick**. Co-Chairs: **P. Porcu**, **P. Quaglino**

- C-01** Prognostic Factors For Stage Progression and Survival in Mycosis Fungoides and Sezary Syndrome: The PROCLIPI Study
Julia Scarisbrick, United Kingdom
- C-02** Review of the measurements of abnormal lymph nodes on imaging and the correlation with N class from the PROspective Cutaneous Lymphoma International Prognostic Index study
Jinah Yoo, United Kingdom
- C-03** T-cell monoclonality in blood and skin correlates with poor response to treatment in mycosis fungoides
Shamir Geller, Israel
- C-04** Erythroderma: analysis of Sézary syndrome criteria in 292 erythrodermic patients
Denis Miyashiro, Brazil

12:00-13:30

Lunch buffet at NH Constanza Hotel

12:00-13:30

PROCLIPI Investigators Meeting (lunch box)

Room 1 at venue (limited places)

13:30-14:20

Session D - Epidemiology

Auditori 8 minutes

Chair: **N. Pimpinelli** Co-Chairs: **I. Litinov**, **M. Pittelkow**

- D-01** Global epidemiology of primary cutaneous lymphomas: a systematic review of relative frequencies and meta-analysis
Gabor Dobos, France
- D-02** Epidemiology of Primary Cutaneous CD8+ T Cell Lymphoma: A United States Population-Based Cohort Analysis using the Surveillance, Epidemiology, and End Results Database
Fatima N. Mirza, United States
- D-03** Racial and age disparities in cardiovascular events may exist in patients with cutaneous T-cell lymphomas
Courtney Johnson, United States
- D-04** Mycosis fungoides in the Chilean pediatric population: a retrospective epidemiological and clinical-pathological study in a Chilean referral center
Francisco Reyes-Baraona, Chile
- D-05** Mycosis Fungoides in children
Paula Enz, Argentina
- D-06** The epidemiology of primary cutaneous gamma/delta T-cell lymphoma: A SEER-18 analysis.
Amrita Goyal, United States

14:20-15:00

Session E - Immunology I

Auditori 10 minutes

Chair: **A. Rook** Co-Chairs: **E. Guenova**, **O. Akilov**

- E-01** Proinflammatory and immunosuppressive cytokines polarize the microenvironment in cutaneous T cell lymphoma and regulate PD-L1 expression
E. Gulsen Gunes, United States
- E-02** Normal Fibroblasts promote Th1 cytokine expression in Myla cells by suppressing TWIST1 expression
Henry K. Wong, United States
- E-03** Anti-CD47 immunotherapy is mediated by cytotoxic CD107a+IFN- γ - NK cells and can be potentiated by interferon- α in cutaneous lymphoma
Oleg Akilov, United States



15:10-15:50

Session F - Immunology II

Auditori 10 minutes

Chair: **M. Girardi** Co-Chairs: **N. Nikbakht**, **E. Papadavid**

- F-01** Mac-1/Mac-2A cells represent a potential model to study IL-13 signaling in SATB1 positive cutaneous ALCL
Yang Wang, China
- F-03** Protein and mRNA expression levels of IL-17A, IL-17F and IL-22 in patients with mycosis fungoides
Despoina Papathelemi, Greece
- F-04** Induction of anti-tumor effect by CD8+ T-cells via CADM1/CRTAM interaction in patients with adult T-cell leukemia lymphoma
Takatoshi Shimauchi, Japan

15:50-16:10

Coffee Break & Poster Viewing

16:15-16:45

HELSINN SATELLITE SYMPOSIUM: Management of chlormethine gel-induced dermatitis: a case-based discussion. **B. Poligone**

Auditori (see detailed programme page 29)

16:45-17:50

Session G - Pathogenesis of Cutaneous Lymphomas

Auditori 10 minutes

Chair: **M. Bagot** Co-Chairs: **S. Koralov**, **L. Geskin**

- G-01** Role of TOX1 and STAT3 pathways in the pathogenesis of cutaneous T-cell lymphoma
Angelina Seffens, United States
- G-02** Probing the causative link between microbial triggers and CTCL progression
Sergei Koralov, United States
- G-03** Standardized flow cytometry (EuroFlow) demonstrates heterogeneous T-cell origin of Sézary lymphoma cells
Safa Najidh, Netherlands
- G-04** Mutational signature analysis reveals a key role for UV radiation in the accumulation of mutations in cutaneous T-cell lymphoma
Christine Jones, United Kingdom
- G-05** Epidermal fatty acid-binding protein is not expressed by tumor cells in advanced mycosis fungoides
Naomi Takahashi-Shishido, Japan
- G-06** Patch lesions of mycosis fungoides patients have a similar skin microbiome profile compared to non-lesional and healthy skin
Wehkamp Ulrike, Germany

18:20

Transfer to the Welcome Cocktail at Palau de la Música (further information in Social Events section)



07:00-08:00 ISCL Board Meeting - Room 2 at venue

07:30 Registration (open all day)

08:00-08:30 Session H - Biomarkers I

Auditori 10 minutes

Chair: M. Sugaya Co-Chairs: A. Gru, C. Klemke

- H-01** Evaluation of blood Sézary markers by means of correlation with apoptosis resistance and clonality
Nicolay Jan, Germany
- H-02** The A allele of rs7096317 is permissive for CD39 expression in CTCL and is a negative prognostic factor in older patients
Christine Jones, United Kingdom
- H-03** Next generation sequencing of TCRbeta gene could be useful in differentiating tumoral stages of mycosis fungoides from CD30 lymphoproliferative disorders over MF plaques
Socorro Maria Rodriguez Pinilla, Spain

08:00-09:00 Session ZI - Clinical Observations I

Room 1 at venue 8 minutes

Chair: R.M. Pujol Co-Chairs: J. Sanches, R. Stranzenbach

- Z-01** Paradoxical response of cutaneous T-cell lymphoma in a patient with concomitant angioimmunoblastic T-cell lymphoma
Amy Johnson, United States
- Z-02** Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 6 patients
María L Espinosa, United States
- Z-03** Response in a patient with refractory folliculotropic mycosis fungoides to a topical hypericin cream activated with fluorescent light
Brian Poligone, United States
- Z-04** Primary cutaneous B-cell lymphoma - case series of two unique cutaneous presentations treated with rituximab
Sarah Noor, United States
- Z-05** Tonsil involvement as a marker of advanced disease in mycosis fungoides
Ildikó Csányi, Hungary
- Z-06** Epstein-Barr Virus-Positive Mucocutaneous ulcer in a patient with Dyskeratosis congenita
Rosa Fornons, Spain
- Z-07** Long lasting complete response to brentuximab vedotin in a patient with primary cutaneous anaplastic large cell lymphoma
June Iriondo, Spain

08:30-09:00 Session I - Biomarkers II

Auditori 10 minutes

Chair: R. Stadler Co-Chairs: U. Wehkamp, H. Wong

- I-01** Identification of CD39 as a potential therapeutic target in Sezary syndrome
Adele De Masson, France
- I-02** The correlation of flow cytometry analysis on skin tissue with immunohistochemistry in cutaneous T-cell lymphoma
Shamir Geller, Israel
- I-03** Overexpression of STAT4 at early stages of mycosis fungoides: coincidence or not?
Ekaterina Grekova, Russian Federation

09:00-09:30 Plenary Session

Chair: R.M. Pujol

Plenary Lecture: Epigenetics in Lymphomagenesis: An Update and Examples for Cutaneous Lymphoma. M. Esteller



09:30-09:45 **Awards Ceremony**
 Chair: **L. Geskin**
 Travel Scholarships
 CLF Young Investigator

09:45-10:00 **Coffee Break**

10:00-10:40 **Session J - Genetic Pathogenesis**
Auditori 10 minutes
 Chair: **M. Vermeer** Co-Chairs: **J. Choi, R. Gniadecki**

- J-01** Comparison of early with advanced Mycosis fungoides lesions on a single cell level to assess potential mediators of disease progression
Patrick M. Brunner, Austria
- J-02** Characterization of tumor evolution of primary T-cell lymphoma using targeted next-generation sequencing panel
Erica Wang, United States
- J-03** Genic signature of Cutaneous T cell lymphoma-associated fibroblasts from Mycosis Fungoides and Sezary Syndrome
Dobos Gabor, France
- J-04** The Effect of Extracellular Matrix and Fibroblasts on Proliferation and Survival of Malignant Cells in Mycosis Fungoides
Burcu Beksac, Turkey

10:00-11:20 **Session Z2 - Clinical Observations II**
Room 1 at venue 8 minutes
 Chair: **F. Foss** Co Chairs: **S. Rosen, J.P. Nicolay**

- Z-08** Clinical, histological and molecular characteristics of anaplastic lymphoma kinase-positive primary cutaneous anaplastic large cell lymphoma
Rutger Melchers, Netherlands
- Z-09** Lupus Erythematosus Tumidus mimicking Primary Cutaneous Marginal Zone B Cell Lymphoma
Megan Trager, United States
- Z-10** Mycosis Fungoides – Granulomatous Slack Skin in association with Hodgkin Lymphoma
Juliana Yumi Massuda, Brazil
- Z-11** Aggressive cutaneous T-cell lymphomas: a series of 19 cases
Montserrat Molgó, Chile
- Z-12** Anetoderma: secondary to syphilis or mycosis fungoides?
Nathalia Lopes Iori, Brazil
- Z-13** CD8+ Mycosis Fungoides Palmaris et Plantaris with Peripheral Blood Involvement
Sara Yumeen, United States
- Z-14** Lymphomatoid drug eruption after treatment of Hepatitis C virus infection with Sofosbuvir: A new described adverse reaction
Mirna Michel, Egypt
- Z-15** Mycosis Fungoides, Lymphomatoid Papulosis and Hodgkin's Lymphoma in the Same Patient: Apropos of a Possible Monoclonal Origin.
Montserrat Molgó, Chile
- Z-16** Pagetoid reticulosis: a rare variant of mycosis fungoides
Elisa Nunes Secamilli, Brazil



10:40-11:20

Session K - Epigenetic Abnormalities

Auditori 10 minutes

Chair: **T. Kupper** Co-Chairs: **Ch. Assaf, M. Matsuoka**

- K-01** Hypomethylation-mediated activation of TMEM244 gene in Sézary cells
Katarzyna Iżykowska, Poland
- K-02** Epigenetic involvement in cutaneous T-cell lymphoma lymphomagenesis
Alain Chebly, France
- K-03** Mycosis fungoides cell line – derived exosomes show a distinct signature of elevated expression of miR-155, miR-1246, and OX40 to promote tumor progression
Lilach Moyal, Israel
- K-04** Transformed mycosis fungoides shows distinct miRNA and mRNA expression profiles compared to classic mycosis fungoides
Cosimo Di Raimondo, United States

11:20-12:00

Session L - Genomic Insights

Auditori 10 minutes

Chair: **S. Whittaker** Co-Chair: **P. Enz**

- L-01** Whole genome sequencing analysis of cutaneous T cell lymphoma
Jaehyuk Choi, United States
- L-02** Novel multi-layered single-cell proteogenomic analysis of patient biospecimens provides unprecedented insight into cellular and molecular landscape of CTCL
Sergei Korolov, United States
- L-03** Functional biological classification of differential gene expression in Sézary syndrome
Henry K. Wong, United States
- L-04** High-throughput sequencing reveals T-cell repertoire restriction in Sézary syndrome and mycosis fungoides
Gonzalo Blanco, Spain

11:20-12:00

Session Z3 - Clinical Observations III

Room 1 at venue 8 minutes

Chair: **E. Kim** Co-Chairs: **P. Quaglino, A. Cozzio**

- Z-17** Maintenance Therapy – a neglected topic
Rudolf Stadler, Germany
- Z-18** Robust graft-versus-lymphoma (GVL) response mimicking cutaneous relapse of T-cell lymphoma
Amy Johnson, United States
- Z-19** Subcutaneous panniculitis-like T-cell lymphoma in the mesentery with associated hemophagocytic syndrome treated by chemotherapy CHOEP, modified HLH 2014 protocol and HDT and auto SCT
Agnieszka Giza, Poland
- Z-20** Aggressive Epidermotropic CD8+ T Cell Lymphoma presenting with targetoid lesions
Mona Abdel-Halim Ibrahim, Egypt
- Z-21** CD4/CD8 double-negative folliculotropic mycosis fungoides/Sézary syndrome presenting as severe leonine facies
Xiaolong Zhou, United States

12:00-13:30

Lunch buffet at NH Constanza Hotel

12:00-13:30

EORTC CLTF Board Meeting

Room 2 at venue (with box lunch)

13:00-13:30

USCLC General Meeting

Room 1 at venue



13:30-14:15

Session M - Molecular Characterization of Rare Cutaneous Lymphomas I

Auditori 8 minutes

Chair: **M. Barry-Beylot** Co-Chairs: **C. McCormack, J. Junkins-Hopkins**

- M-01** Molecular study of Subcutaneous Panniculitis-like T-cell lymphoma, Lupus panniculitis and overlap cases
Salma Machan, Spain
- M-02** Germline TIM-3 mutations characterize sub-cutaneous panniculitis-like T2 cell lymphomas with hemophagocytic lymphohistiocytic syndrome
Christopher McCormack, Australia
- M-03** Comparative Genomic Analysis of CD30+ Lymphoproliferative Disorders
Farah Abdulla, United States
- M-04** Systemic and cutaneous anaplastic T-cell lymphomas differ in their expression profile
Socorro Maria Rodriguez Pinilla, Spain
- M-05** Clonal relationship between Blastic Plasmacytoid Dendritic Cell Neoplasm and Myeloid Neoplasms
Luis Colomo, Spain

13:30-14:45

Session Z4 - Clinical Observations IV

Room 1 at venue 8 minutes

Chair: **R. Knobler** Co-Chairs: **P. Porcu, P. Quaglino**

- Z-22** Ain-Shams Cutaneous Lymphoma Clinic – suggested guidelines for the treatment of mycosis fungoides in countries with limited resources
Mona Abdel-Halim Ibrahim, Egypt
- Z-23** Patients with mycosis fungoides are at increased risk of lung cancer: a systematic review and population-based analysis
Amrita Goyal, United States
- Z-24** Epidemiological analysis and review of histopathological parameters of patients diagnosed with mycosis fungoides and its variants in follow-up at State University of Campinas
Natalia Naomi Suzuki, Brazil
- Z-25** An overview: Our experience of microbiological causes of inpatient admissions for patients with Mycosis Fungoides and Sézary's Syndrome at Peter MacCallum Cancer Centre, Melbourne, Australia
Odette Buelens, Australia
- Z-26** The use of GATA3 in challenging cases of CD30+ Mycosis fungoides (MF) versus anaplastic large cell lymphoma (ALCL)
Isabella Parente Almeida, Brazil
- Z-27** CD30 expression is detectable in most rare cutaneous lymphoma subtypes
Wehkamp Ulrike, Germany
- Z-28** CD8+ mycosis fungoides with diverse atypical clinical and pathological presentations
Mona Ibrahim, Egypt
- Z-29** The therapeutic potential of Cannabinoids from Cannabis sativa extracts for mycosis fungoides / Sézary syndrome - an in vitro and ex vivo study
Iris Amitay-Laish, Israel



14:15-14:45

Session N - Molecular Characterization of Rare Cutaneous Lymphomas II

Auditori 10 minutes

Chair: [C. Querfeld](#) Co-Chairs: [M. Pulitzer](#), [M. Molgo](#)

- N-01** Cellular Origins and Genetic Landscape of Cutaneous Gamma Delta T Cell Lymphomas
[Jay Daniels](#), United States
- N-02** Genomic and Transcriptomic Characterization of Primary Cutaneous Gamma/Delta T-cell Lymphomas Reveals Distinct Genetic Alterations and Enrichment for Various Signaling Pathways
[Melissa Pulitzer](#), United States
- N-03** Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm
[Armando Bastidas Torres](#), Netherlands

14:45-15:30

Formal Poster Session I - Even-numbered posters presentation & Coffee Break

Room Win. Level 0

15:30-16:00

KYOWA SATELLITE SYMPOSIO: Clinical importance of assessing blood involvement in CTCL

[M. Vermeer](#), [S.L. Morris](#)

Auditori (see detailed programme page 29)

16:00-16:50

Session O - Cutaneous B-Cell Lymphomas

Auditori 8 minutes

Chair: [A. Cozzio](#) Co-Chairs: [O. Servitje](#), [M. Batistella](#)

- O-01** Primary Cutaneous Follicular Lymphoma is Genetically Distinct from Secondary Cutaneous Follicular Lymphoma
[Xiaolong \(alan\) Zhou](#), United States
- O-02** Challenges in the diagnosis of primary cutaneous large B-cell-lymphomas
[Merlio Jean-Philippe](#), France
- O-03** Mutations of the B-cell receptor pathway confer chemoresistance in primary cutaneous diffuse large B-cell lymphoma leg-type
[Gros Audrey](#), France
- O-04** Limited diagnostic value of HANS and Lymph2CX in differentiating between primary cutaneous follicle center lymphoma and primary cutaneous diffuse large B-cell lymphoma, leg type
[Anne M.R. Schrader](#), Netherlands
- O-05** Primary Cutaneous Marginal Zone B-Cell Lymphoma in Children and Young Adults
[Margarita Jo-Velasco](#), Spain
- O-06** First - line radiotherapy does not improve the risk of disease progression in primary cutaneous diffuse large B cell lymphoma, leg type
[Florentia Dimitriou](#), Switzerland

16:00-16:50

Session P - Quality of Life

Room 1 at venue 10 minutes

Chair: **A. Musiek** Co-Chairs: **F. Gallardo, J. Zic**

- P-01** The evaluation of the QoL and daily functioning of Polish patients with Cutaneous T-Cell Lymphoma Cognosco LLC commissioned by the firm Takeda Pharma LLC
Agnieszka Giza, Poland
- P-02** Skin-specific quality of life in cutaneous T-cell lymphoma compared with other dermatologic diseases
Trisha Bhat, United States
- P-03** Qualitative assessment of the quality of life in patients with cutaneous T-cell lymphoma (CTCL)
Trisha Bhat, United States
- P-04** The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas
Xochiquetzal Martinez, United States
- P-05** Psychiatric comorbidity in patients with cutaneous T-cell lymphoma (CTCL)
Trisha Bhat, United States

16:50-18:15

Session Q - Discussion & Controversies

Chair: **E. Hodak** Co-chairs: **J. Guitart, R. Hoppe**

LyP: lymphoma or not (30 minutes) / **J. Hodak vs W. Kempf**

SS/MF: 1 or 2 diseases (30 minutes) / **M. Veermer vs J. Choi**

Will we ever "cure" advanced CTCL? (25 minutes) / **S. Horwitz vs H. Prince**

20:00

Transfer to the Congress Dinner at La Llotja de Mar (further information in Social Events section)

07:00-08:00 **USCLC Board Meeting**
Room 2 at venue

07:30 **Registration** (open all day)

08:00-09:00 **Session R - Preclinical Development of Personalized Therapies I**
Auditori 10 minutes
Chair: [L. Geskin](#) Co-Chairs: [M. Khodadoust](#), [S. Horwitz](#)

- R-01** Pre-clinical precision therapeutic targeting NF-kB in patients with Sézary syndrome
[Fernando Gallardo](#), Spain
- R-02** Synergistic Therapeutic Drug Screening Using Jak Inhibition for CTCL
[Sara Yumeen](#), United States
- R-03** Romidepsin combination therapies involving regulation of the JAK/STAT pathway inhibit tumor proliferation in cutaneous T-cell lymphoma
[Teresa Palomero](#), United States
- R-04** Phospholipase C Gamma 1 (PLCG1) mutations in Sézary cells drive NFkB, AP-1 and NFAT signalling and mediate resistance to the calcineurin inhibitor Tacrolimus
[Charlotte E. Flanagan](#), United Kingdom
- R-05** Screening for Novel Combination Treatments for Cutaneous T Cell Lymphoma for Expedited Development
[Fatima N. Mirza](#), United States
- R-06** The synergistic pro-apoptotic effect of HDAC and PARP-1 inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1
[Oleg Akilov](#), United States

09:00-10:00 **Session S - Preclinical Development of Personalized Therapies II**
Auditori 10 minutes
Chair: [S. Hwang](#) Co-Chairs: [W. Weng](#), [F. Trautinger](#)

- S-01** A small molecule CCR2 antagonist depletes tumor macrophages and synergizes with anti-PD1 in a murine model of cutaneous T cell lymphoma
[Sam Hwang](#), United States
- S-02** Investigating the role for POT1 gene dysfunction in Primary Cutaneous T-cell Lymphoma
[Farrah Bakr](#), United Kingdom
- S-04** Integrin $\alpha V\beta 3$ inhibition improves rexinoids antitumoral actions on cutaneous T cell lymphoma (CTCL)
[Maria Florencia Cayrol](#), Argentina
- S-05** HDAC inhibitor resminostat counteracts disease-related gene expression and cytokine secretion in CTCL cells
[Gundula Streubel](#), Germany
- S-06** Single cell RNA sequencing analysis to define therapeutic targets in cutaneous T-cell lymphoma
[Christiane Querfeld](#), United States

10:00-10:45 **Formal Poster Session II - Odd-numbered posters presentation & Coffee Break**
Room Win (level 0)

10:45-11:30

Session T - Novel Therapeutics*Auditori 10 minutes*Chair: **P. Porcu** Co-Chairs: **M. Bagot, O. Akilov**

- T-01** Cusatuzumab for Treatment of CD70-positive Relapsed/Refractory Cutaneous T-cell Lymphoma in a Phase 1/2 Clinical Trial
Martine Bagot, France
- T-02** A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, a STAT3 Inhibitor, for Mycosis Fungoides (MF)
Malgorzata Sokołowska-Wojdyło, Poland
- T-03** High dose rate brachytherapy for the treatment of primary cutaneous lymphoma at complex sites and complex curves skin surfaces
Van Ren Sim, United Kingdom
- T-04** Intralesional oncolytic virotherapy results in tumor regression associated with the influx of cytotoxic T cells in cutaneous B-cell lymphoma
Egle Ramelyte, Switzerland

11:30-12:10

Session U - Stem Cell Transplant*Auditori 10 minutes*Chair: **M. Duvic** Co-Chairs: **J. Zain, H. Prince**

- U-01** A phase II prospective study using non-myeloablative allogeneic transplantation in patients with advanced stage mycosis fungoides and Sezary syndrome
Wen-Kai Weng, United States
- U-02** Allogeneic hematopoietic stem cell transplantation as a curative treatment strategy for patients with advanced mycosis fungoides and Sézary syndrome: 2019 update of the Milan experience
Francesco Onida, Italy
- U-03** Non-myeloablative allogeneic stem cell transplantation using TSEB TLI and ATG for Mycosis Fungoides(MF) and Sezary Syndrome(SS). Medium term results from a large single centre cohort
Stephen Morris, United Kingdom
- U-04** Outcomes for Allogeneic Stem Cell Transplantation in Refractory Cutaneous Lymphomas
Francine Foss, United States

12:15-12:30

ISCL General Meeting*Auditori*

12:15-13:15

Lunch box at venue

13:15-14:15

TAKEDA SYMPOSIUM: Current treatment patterns and targeted agents in the management of CTCL.**P. Ortíz Romero, J. Scarisbrick***Auditori* (see detailed programme page 29)

14:15-15:15

Session V - Therapeutics I

Auditori 10 minutes

Chair: [Y.Kim](#) Co-Chairs: [J. Zain](#), [S. Horwitz](#)

- V-01** Therapy of Brentuximab vedotin in Cutaneous T-cell lymphomas. Multi institutional analysis
[Marcio Andrade Campos](#), Spain
- V-02** Brentuximab vedotin treatment produces superior skin responses and fewer stage progressions than oral bexarotene, chemotherapy, and skin-directed therapy in large cell transformed mycosis fungoides
[Megan O'donnell](#), United States
- V-03** Real-life experience on the use of brentuximab vedotin on nine mycosis fungoides patients: time to re-discuss treatment protocols?
[Denis Miyashiro](#), Brazil
- V-04** Brentuximab vedotin (BV) and lenalidomide (Len) in relapsed/refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas; interim results of a phase II trial
[Basem William](#), United States
- V-05** Final ALCANZA results: brentuximab vedotin versus physician's choice in previously treated CD30-positive cutaneous T-cell lymphoma (mycosis fungoides or primary cutaneous anaplastic large cell lymphoma)
[Julia Scarisbrick](#), United Kingdom
- V-06** Brentuximab vedotin for relapsed/refractory Sézary syndrome: a single-center experience
[Daniel Lewis](#), United States

15:15-15:45

Session W - Therapeutics & Clinical Trials II

Auditori 10 minutes

Chair: [C. McCormack](#) Co-Chairs: [E.Kim](#), [P. Ortiz-Romero](#)

- W-01** Resolution of Sézary Syndrome after Combination of Mogamulizumab with Pegylated Interferon $\alpha 2$ -a is Mediated by CD56dim NKp30+ IFN- γ + NK Cells
[Oleg Akilov](#), United States
- W-02** A Novel Regimen of Interferon Gamma, Bexarotene, Photopheresis and 12 Gy Total Skin Electron Beam Can Produce Long Term Remission: Clinical, Immunological and Molecular Analysis
[Alain H Rook](#), United States
- W-03** Clinical activity and safety of low-dose total skin electron beam therapy combined with mogamulizumab in refractory Sézary syndrome: support for a clinical trial in CTCL
[Youn H Kim](#), United States

15:45-16:00

Coffee Break



16:00-17:00

Session X - Observations and Perspectives*Auditori 8 minutes*Chair: **E. Olsen** Co-Chairs: **R. Knobler**

- X-01** Treatment of advanced-phase mycosis fungoides: results from the prospective Cutaneous Lymphoma International Study (PROCLIP study)
Pietro Quaglino, Italy
- X-02** What happens when an effective anti-CTCL drug is discontinued from production?
Bethanie Rooke, United Kingdom
- X-03** Improved survival for skin-primary presentation of adult T-cell leukemia/lymphoma (ATLL)
Amrita Goyal, United States
- X-04** Treatment and prognosis of rare patients with a primary cutaneous CD30-positive lymphoproliferative disorder who develop extracutaneous localisations
Rutger Melchers, Netherlands
- X-05** Winkelmann regimen: oral Chlorambucil for Mycosis Fungoides and Sezary syndrome
Gowardhanan Doss, United Kingdom
- X-06** Characterization of Rash Associated with Mogamulizumab
Kelsey E. Hirotsu, United States
- X-07** Characterization of the Histopathologic and Molecular Features of Rash Associated with Mogamulizumab
Jennifer Y. Wang, United States

16:00-17:00

Session Y - Topical Chemotherapy*Room 1 at venue 10 minutes*Chair: **J. Sanches** Co-Chairs: **M. Bagot**, **E. Hodak**

- Y-01** Real-life experience with chlormethine gel: moving beyond clinical trial data
Hadas Prag Naveh, Israel
- Y-02** Mechlorethamine treatment duration as a function of clinician-level patient volume for mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL)
Christiane Querfeld, United States
- Y-03** The PROVe study: real-world experience with chlormethine gel and other therapies in the treatment of mycosis-fungoides cutaneous T-cell lymphoma patients
Ellen Kim, United States
- Y-04** Incidence and types of contact dermatitis after chlormethine gel treatment in patients with mycosis fungoides-type cutaneous T-cell lymphoma: the MIDAS study
Elain S. Gilmore, United States

17:00-17:15

Closing Remarks*Auditori*

POSTER SESSION I: EVEN-NUMBERED POSTERS

THURSDAY, 13TH FEBRUARY 2020 FROM 14:45H TO 15:30H

POSTER SESSION II: ODD-NUMBERED POSTERS

FRIDAY, 14TH FEBRUARY 2020 FROM 10:00H TO 10:45H

PRIMARY CUTANEOUS LYMPHOMA, CLINICAL & PATHOLOGICAL - MYCOSIS FUNGOIDES

- 001** Understanding the function of CD30 in cutaneous T-cell lymphoma – implications for therapy and prognosis
Jana Dorothea Braun, Germany
- 002** Low-Dose Gemcitabine Therapy in Cutaneous T-Cell Lymphomas - "Real-life" Data of the German Cutaneous Lymphoma Network
Blazejak Christoph, Germany
- 003** Granulomatous Mycosis Fungoides with associated local thrombotic vasculopathy
Andrea Combalia, Spain
- 004** Histopathological criteria for the diagnosis of early and erythrodermic mycosis fungoides
Flavia De Freire Cassia, Brazil
- 005** Mycosis fungoides successfully treated with PUVA and Acitretin
Flavia De Freire Cassia, Brazil
- 006** Epidemiological, clinical and pathological profile of outpatients with mycosis fungoides: high prevalence of hypocromic variant in a miscigenated population
Flavia De Freire Cassia, Brazil
- 007** Subcutaneous Panniculitis-like T cell Lymphoma
Flavia De Freire Cassia, Brazil
- 008** High throughput sequencing of the T-cell receptor beta gene in lesional skin in the diagnosis of primary cutaneous T-cell lymphoma: analysis of 76 patients
Adèle De Masson, France
- 009** Pilot study of a novel therapeutic approach for refractory advanced stage folliculotropic mycosis fungoides
Christina Del Guzzo, United States
- 010** Diagnostic challenge: Pityriasis lichenoides, Mycosis fungoides or both?
Isabel Gainza Apraiz, Spain
- 011** Increased risk of malignancy in mycosis fungoides: A single-center perspective
Amrita Goyal, United States
- 012** PUVA and interferon $\alpha 2b$ combined therapy for patients with mycosis fungoides at different stages in Russia
Ekaterina Grekova, Russian Federation
- 013** The diagnostic dilemma of large CD30 positive cell transformation in the lymph nodes
Mona Ibrahim, Egypt
- 014** Redefining the pathogenesis of Mycosis Fungoides
Aishwarya Iyer, Canada
- 015** Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma
Aishwarya Iyer, Canada
- 016** Alopecia areata universalis as an atypical presentation of classic Mycosis fungoides
Helena Iznardo, Spain
- 017** Improved overall survival after multimodality treatment in a single-institution cohort of 36 patients with folliculotropic mycosis fungoides
Caroline Laggis, United States
- 018** Analysis of expression, and function of meiosis regulatory genes and LINE-1 retrotransposon reactivation in Cutaneous T-Cell Lymphomas (CTCL)
Ivan Litvinov, Canada
- 019** Mycosis fungoides with large cell transformation
Ane Lobato Izagirre, Spain



- 020** Diagnostic and prognostic value of genotypic analysis in cutaneous lymphoproliferative processes using the standardized BIOMED-2 polymerase chain reaction protocols
Daniel López Aventín, Spain
- 021** Hypereosinophilic syndrome with T- cell lymphoma development
Mikel Meruelo Ruano, Spain
- 022** Papular mycosis fungoides: report of three cases
Miren Josune Michelena, Spain
- 023** Clinicopathological features of Mycosis Fungoides with CD8+ and CD56+ phenotype
Natalia Papaleo, Spain
- 024** Hematologic disorders in patients with mycosis fungoides: results from a tertiary referral center in Northern Greece
Aikaterini Patsatsi, Greece
- 025** Brentuximab side-effects in mycosis fungoides patients
Alessandro Pileri, Italy
- 026** Molecular signature patterns related to the development of contact dermatitis in patients with mycosis fungoides-type cutaneous T-cell lymphoma treated with chlormethine gel
Brian Poligone, United States
- 027** Expression of CCR3 and CCR4 suggests a poor prognosis in mycosis fungoides and Sézary syndrome
Hiraku Suga, Japan
- 028** Diagnosis in the hands: a rare variant of mycosis fungoides
Natalia Naomi Suzuki, Brazil
- 029** A Case of Mogamulizumab Induced Lichenoid Reaction
Megan Trager, United States
- 030** Intraocular involvement in mycosis fungoides
Peru Urigoitia Ugalde, Spain

PRIMARY CUTANEOUS LYMPHOMA, CLINICAL & PATHOLOGICAL - CD30+ LYMPHOPROLIFERATIVE DISORDERS

- 032** Pitfalls of pseudoepitheliomatous hyperplasia in CD30+ lymphoproliferative disorders
Michael Davis, United States
- 033** Primary Cutaneous CD30-Positive Anaplastic Large Cell Lymphoma
Francisco Javier De La Torre Gomar, Spain
- 034** Primary cutaneous anaplastic large cell lymphoma CD30+ treated with Brentuximab
Nerea Gonzalez Romero, Spain
- 035** The importance of differentiating between Mycosis Fungoides with CD30 positive large cell transformation and Mycosis Fungoides with co-existent primary cutaneous Anaplastic Large Cell Lymphoma
Christopher McCormack, Australia
- 036** Prognosis of primary cutaneous anaplastic large cell lymphoma (pcALCL) with clinically superficial nodes at diagnostic
D'incan Michel, France
- 037** Lymphomatoid Papulosis: A retrospective review of clinical characteristics, symptomatology, treatments, and associated malignancies at a single-institution
Sarah Noor, United States
- 038** Primary cutaneous CD30+ lymphoproliferative disorders in HIV+: a single center case series
Josep Riera Monroig, Spain
- 039** Facial primary cutaneous CD30+ lymphoproliferative disorder mimicking keratoacanthoma: two case reports
Josep Riera-Monroig, Spain
- 040** Peripheral T-cell lymphoma not otherwise specified involving the skin in a young female patient
Fernanda Rytenband, Brazil



PRIMARY CUTANEOUS LYMPHOMA, CLINICAL & PATHOLOGICAL - PRIMARY CUTANEOUS B-CELL LYMPHOMAS, INCLUDING FOLLICLE CENTER LYMPHOMA, MARGINAL ZONE, AND DIFFUSE LARGE B-CELL LYMPHOMA

- 041** Marginal zone lymphoma of the toes
Maubec Eve, France
- 042** Primary cutaneous follicle center lymphoma with unusual, longterm poor outcome
Irene Lastrucci, Italy
- 043** Long-term CD30+ diffuse primary cutaneous large cell B-cell lymphoma
Rosa Maria Martí Laborda, Spain
- 044** Flowcytometry of the skin can be a useful diagnostic tool for primary cutaneous B-cell lymphoma and cutaneous B-cell pseudolymphoma
Yuki Nakagawa, Japan
- 045** Two patients with cutaneous B-cell tumors sharing the same MYD88 mutation with previous systemic diffuse large B-cell lymphomas. Divergent evolution?
Lucia Prieto Torres, Spain
- 046** Epidermotropic B-cell lymphoma. A peculiar histopathological subtype often associated with extranodal (splenic) marginal zone B-cell lymphoma
Roger Rovira-López, Spain
- 047** Primary cutaneous marginal zone B-cell lymphoma associated to Amyloid deposit
Amaia Saenz Aguirre, Spain
- 048** Cutaneous involvement in Waldenström macroglobulinemia
Sarah Stien, France
- 049** Primary cutaneous follicle center lymphoma (PCFCL) - Does location matter? A clinical and histological comparison between scalp involvement versus other sites
Christina J. Walker, United States

PRIMARY CUTANEOUS LYMPHOMA, CLINICAL & PATHOLOGICAL - UNCOMMON PRIMARY CUTANEOUS LYMPHOMAS

- 050** A case of an Epstein-Barr Virus-Positive Mucocutaneous ulcer in a patient treated with abatacept
Iñigo Aranguren-López, Spain
- 051** Primary cutaneous gamma-delta T cell lymphoma, a potential mimicker of Lupus erythematosus panniculitis: a case report
Francisco Javier De La Torre Gomar, Spain
- 052** Epstein-Barr virus positive mucocutaneous ulcer accompanied with B-chronic lymphocytic leukemia
Kazuyasu Fujii, Japan
- 053** Monomorphic epitheliotropic intestinal $\gamma\delta$ T-cell lymphoma with secondary cutaneous involvement. A diagnostic challenge
Fernando Gallardo, Spain
- 054** Epstein-Barr virus-associated plasmablastic lymphoma
Marion Jost, Germany
- 055** Post-transplant lymphoproliferative disorder manifesting as a solitary erythematous indurated plaque on the leg
Ingrid Lopez-Lerma, Spain
- 056** Primary cutaneous CD4+ small-to medium-sized T-cell lymphoproliferative disorder: Clinical, histopathological features and follow-up in 9 patients
Angel Manuel Rosell-Diaz, Spain
- 057** Cutaneous lymphoproliferative disorder of small and medium-sized CD4 positive T cell- a case series of 3 patients
Pau Rosés Gibert, Spain
- 058** Complete remission of aggressive epidermotropic CD8+ T-cell lymphoma after total skin electron beam therapy. An indolent subtype, diagnostic failure or too early declaration of recovery?
József Szakonyi, Hungary
- 059** Two cases of cyclosporin-refractory subcutaneous panniculitis-like T-cell lymphoma
József Szakonyi, Hungary

BASIC RESEARCH - ETIOLOGY AND PATHOMECHANISMS - GENOMICS, GENETICS AND EPIGENETICS

- 060** Abnormal DNA methylation gradients in mycosis fungoides and Sézary syndrome
Henry K. Wong, United States

BASIC RESEARCH - ETIOLOGY AND PATHOMECHANISMS - MOLECULAR PATHWAYS

- 061** Worsening of mycosis fungoides after immunotherapy with ipilimumab and nivolumab
Pyl Jeroen, Belgium

BASIC RESEARCH - ETIOLOGY AND PATHOMECHANISMS - IMMUNOLOGY, HOST RESPONSE AND TUMOR MICROENVIRONMENT

- 062** Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma
Niels Ødum, Denmark
- 063** Characterizing the macrophages involved in granulomatous slack skin
Ulrike Wehkamp, Germany

TRANSLATIONAL AND CLINICAL RESEARCH - BIOMARKERS & PATHOGENESIS

- 064** Diagnostic impact of circulating microRNAs in Cutaneous T-cell lymphoma
Evangelia Papadavid, Greece
- 065** TOX-1 expression in mycosis fungoides
Alessandro Pileri, Italy

TRANSLATIONAL AND CLINICAL RESEARCH - NEW TARGETS IN THE TREATMENT OF CUTANEOUS LYMPHOMAS

- 066** Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47
Hiroaki Kamijo, Japan
- 067** Increased delta-like ligand 4 expression in mycosis fungoides
Tomomitsu Miyagaki, Japan
- 068** Total Skin Electron Beam Therapy as skin conditioning for Stem-Cell Transplantation in Sézary Syndrome
Lula María Nieto Benito, Spain

TRANSLATIONAL AND CLINICAL RESEARCH - COMBINATION THERAPIES: PROSPECTS AND PROBLEMS

- 069** Resminostat increases NK cell-mediated lysis of malignant cells and enhances the function of opsonizing antibodies
Borgmann Matthias, Germany

TRANSLATIONAL AND CLINICAL RESEARCH - CLINICAL TRIALS

- 070** Naloxone Lotion for Relief of Pruritus Associated with Cutaneous T-Cell Lymphoma (CTCL): Phase 3 Development Update
Scott Phillips, United States
- 071** Phase I study of Cobomarsen, a miR-155 inhibitor, in patients with aggressive HTLV-1 associated ATLL: disease stabilization and biomarker analysis
Francine Foss, United States
- 072** Multicentre, double blind, trial evaluating resminostat for maintenance treatment of advanced stage MF or SS



patients after disease control with systemic therapy – RESMAIN study
Rudolf Stadler, Germany

TRANSLATIONAL AND CLINICAL RESEARCH - MULTINATIONAL COLLABORATIVE STUDIES

- 073** Positron Emission Tomography (PET) Scan as a Surrogate for Lymph Node Biopsies in Mycosis Fungoides and Sezary Syndrome
Emmanuella Guenova, Switzerland

PATIENT CARE IN CUTANEOUS LYMPHOMA - PERSONALIZED MEDICINE

- 074** Local experience of phototherapy in managing Mycosis Fungoides
Amina Khalid, United Kingdom

PATIENT CARE IN CUTANEOUS LYMPHOMA - GUIDELINES

- 075** Italian expert-based recommendations on the use of photo(chemo)therapy in the management of Mycosis Fungoides and Sezary Syndrome: results of an E- Delphi consensus
Vieri Grandi, United Kingdom

PATIENT CARE IN CUTANEOUS LYMPHOMA - AVAILABLE THERAPIES - NEW TARGETS

- 076** Extracorporeal photopheresis for the treatment of patients with Sezary's syndrome and erythrodermic MF: real-world data
Leonardo J Enciso Olivera, Colombia

PATIENT CARE IN CUTANEOUS LYMPHOMA - QUALITY OF LIFE/SUPPORTIVE THERAPIES

- 077** Burden of Disease in Early MF of Cutaneous T-Cell Lymphoma (CTCL): Consistent Results from Clinician Interviews and Focus Group Participants
Martine Bagot, France
- 078** Cutaneous lymphoma patients' perceptions regarding cannabis: a survey study
Tyler Coolman, United States
- 079** Aprepitant in refractory pruritus of systemic lymphoproliferative disorders
Ana Pulido-Perez, Spain
- 080** Paying the Price of CTCL: An analysis of recent trends in skin-directed and systemic treatment costs for Cutaneous T-cell Lymphoma
Jaclyn M. Rosenthal, United States
- 081** Health care use among mycosis fungoides and Sézary syndrome patients in 1998-2016 - a population-wide study
Liisa Vakeva, Finland

PATIENT CARE IN CUTANEOUS LYMPHOMA - DIFFICULT TO TREAT/RARE LYMPHOMAS

- 082** Case report: venetoclax for treatment of relapsed/refractory mycosis fungoides, tumor stage, with folliculotropism and large cell transformation
Xochiquetzal Martinez, United States

HELSINN

WEDNESDAY, 12 FEBRUARY 2020

TIME: 16:15h - 16:45h

ROOM: Auditori - Plenary Room

MANAGEMENT OF CHLORMETHINE GEL-INDUCED DERMATITIS: A CASE-BASED DISCUSSION

SPEAKER

Brian Poligone, MD, PhD, Medical Director, Rochester Skin Lymphoma Medical Group, Fairport, NY, USA

PROGRAM

16:15-16:20 Opening and welcome

16:20-16:40 Management of chlormethine gel-induced dermatitis: a case-based discussion

16:40-16:45 Q&A and closing

KYOWA KIRIN

THURSDAY, 13 FEBRUARY 2020

TIME: 15:30h - 16:00h

ROOM: Auditori - Plenary Room

CLINICAL IMPORTANCE OF ASSESSING BLOOD INVOLVEMENT IN CTCL

PROGRAMME:

Welcome and introduction

Maarten Vermeer, MD, PhD, Leiden University Medical Centre (LUMC), Leiden, Netherlands

Standardizing the measurement of blood involvement in CTCL patients

Maarten Vermeer, MD, PhD

Stephen L. Morris, MBBS, MRCP, FRCR, Guy's and St Thomas' NHS Foundation Trust, London, UK

What is the prognostic relevance and treatment implications of blood involvement in CTCL?

Maarten Vermeer, MD, PhD, **Stephen L. Morris**, MBBS, MRCP, FRCR

Discussion and conclusions

Maarten Vermeer, MD, PhD, **Stephen L. Morris**, MBBS, MRCP, FRCR

TAKEDA

FRIDAY, 14 FEBRUARY 2020

TIME: 13:15h -14:15h

ROOM: Auditori - Plenary Room

CURRENT TREATMENT PATTERNS AND TARGETED AGENTS IN THE MANAGEMENT OF CTCL

13:15-13:20

Welcome and introductions. **Prof. Pablo Ortiz Romero**, Hospital Universitario 12 de Octubre, Madrid, Spain

13:20-13:35

Contemporary European treatment patterns and responses in relapsed/refractory CTCL **Prof. Pablo Ortiz Romero**

13:35-13:50

Recently approved targeted agents in the management of CTCL. **Prof. Julia Scarisbrick**, Queen Elizabeth Hospital, Birmingham, UK

13:50-14:10

Sharing clinical practice: real-world case studies. **Prof. Julia Scarisbrick**, **Prof. Pablo Ortiz Romero**

14:10-14:15

Q&A **Prof. Julia Scarisbrick**, **Prof. Pablo Ortiz Romero**



ORAL PRESENTATION INFORMATION AND GUIDELINES

The time allocated to your ORAL presentation is 6 minutes lecture plus 2 minutes for questions/debate or 8 minutes lecture plus 2 minutes for questions/debate following your session. Please note that the session chairs will be strict with regard to presentation timing in order to avoid any delay in the scheduled programme.

AUDIOVISUAL

Presenters are requested to prepare an oral presentation. Save your talk in Microsoft Power point format, (either .ppt or .pptx), at slides at 16:9 (for presentations in Room Auditori) or 4:3 (for presentations in Room 1). Please use the presentation code provided in the guidelines presentation letter for naming your talk.

Make sure any audio or video that you wish to present is embedded such that the file can be presented as standalone. Please upload your presentation minimum 2 hours prior your presentation in the speaker room (open from 7:30h to 18:00h) located in the Level 2 in case that your presentation are in the Auditori. If your presentation is in Room 1 you must go directly to the room.

You may not bring your laptop to the podium.

You should sit in the front row designated speaker space near the stage as your session begins to allow you to mount the stage quickly. If you do not approach the stage when your name is called, you will forfeit your spot and the Chair will move on to the next talk.

HANDOUT OF PRESENTATIONS

The handouts of the abstracts selected as oral presentation are included in the memory stick delivered together with the congress documentation and they will be published on the website after the congress.

POSTER PRESENTATION GUIDELINES

POSTER SESSIONS

During Poster Session I, Thursday, February 13th, 2020 from 14:45h to 15:30h, the presenters of the even-numbered posters must be attended.

During the Poster Session II, Friday, February 14th, 2020 from 10:00h to 10:45h, only the presenters of the odd-numbered posters must be attended.

POSTER VIEWING SCHEDULE:

Wednesday, February 12th, 2020: from 10:45h to 11:15h and from 15:45h to 16:15h.

Thursday, February 13th, 2020: from 9:45h to 10:00h

Poster presenters are responsible for printing their own poster prior to the Congress and bringing it to the Congress. Please note that no printing service is available on site.


Please ensure that your poster is fixed to the board corresponding to your final presentation code. The boards will be allocated by topics.

Material will be available for the hanging of posters at the Technical Secretariat.

CONGRESS VENUE

Auditorio Axa

- > Av. Diagonal, 547
- > 08029 Barcelona



TECHNICAL SECRETARIAT

GRUPO PACIFICO

The power of meeting

Marià Cubí 4 | 08006 Barcelona (SPAIN)
T. +34 932388777 | F. +34 932387488
Email: 4wccI2020@pacifico-meetings.com

MEALS COFFEE AND LUNCHES

The official lunches included in the registration fees, will be provided for Congress. Wednesday, February 12th and Thursday, February 13th, the lunches will take place at Hotel NH Constanza, next door of the congress venue, (1 minute walking). The lunch on Friday, will be served in the congress venue, (lunch box). Please, present your lunch ticket for each day.

Coffee breaks will be served in the Auditori Foyer (exhibition area) and Room Win (poster area)

TRANSFERS

The transfers to the Welcome Cocktail and Congress dinner are provided for the Congress. After the event, return to the venue.

Meeting point for departure by bus: Diagonal Street in front of the Axa Auditorium.

Welcome Cocktail at Palau de la Música: Transfer at 18:20h
Congress Dinner at Lotja de Mar: Transfer at 20:00h

Be on time, please!



WELCOME COCKTAIL

PALAU DE LA MÚSICA CATALANA

Wednesday 12th February 2020 at 19:00h.

> Included in Congress registration fee. Please wear your badge to access.

Guide visit to the Palau de la Música and Welcome Cocktail.

The Palau de la Música Catalana is an architectural jewel of Catalan Art Nouveau, the only concert venue in this style to be listed as a World Heritage Site by UNESCO (4th December 1997), which today represents an essential landmark in the cultural and social life of Catalonia. Moreover it represents a symbolic emotional heritage for a whole people who identify with its history.

Sponsored by



CONGRESS DINNER

LLOTJA DE MAR

Thursday 13rd February 2020 at 20:30h

> Congress dinner ticket (attendee): 50€

> Congress dinner ticket (guests): 135€

> The corresponding ticket will be required to access.

The Llotja de Mar or “Sea Exchange” is one of Barcelona’s most emblematic buildings, and it has always been the flagship of a dynamic civil society committed to Catalonia’s economic and social progress.



The Llotja consists of a number of superimposed buildings: to the 14th-century Gothic nucleus, formed by what later became known as the Contracting and Consular Halls, there was added in the 15th century the collateral nave, which contains the Gilded Hall. In the 16th century new enlargements were made, and finally, in the late 18th century, the Neoclassical exterior that we see today was constructed.

LANGUAGE

The official language of the Congress is English. No translation will be provided.

INSURANCE AND DISCLAIMER

4th WCCL accepts no liability for injuries and/or losses of whatever nature incurred by participants and/or accompanying persons, nor for loss or damage to their luggage and/or personal belongings. Please check the validity of your own insurance.

BADGES

Badges will be handed out to participants at the Technical Secretariat Desk. For security reasons, please wear your badge at all times.

For the lunches and Congress Dinner, it will also be necessary to present the corresponding ticket.



A

Abdala, Suraya Maria	Z-24
Abdelbary, Haitham	Z-22, Z-28
Abdo, André	C-04
Abdulla, Farah	K-04, L-01, M-03, N-01, P-04, 082
Abrantes Giannotti, Marcelo	Z-26, 063
Acheampong, Daniel	L-03
Acle, Renata	D-04, Z-11
Adad, Marcio Antonio Haro	Z-16
Adamski, Henri	048
Agirre, Amaia S.	Z-02
Agostinelli, Claudio	025, 065
Ajjampura, Vinayaka C.	Z-29
Akilov, Oleg	C-01, E-03, R-06, V-05, W-01
Alaibac, Mauro	075
Alani, Ali	B-06
Alberti Violetti, Silvia	U-02, 075
Aldridge, Sarah	T-03
Alekseeva, Ekaterina	I-03
Alexander-Savino, Carolina V.	Y-04, Z-03, 026
Alfonso Martin, Juan Luis	M-01
Alhafnawi, Mohammed	Z-03
Alleri, Angelica C.	T-01
Almeida, J.	G-03
Alos, Lluçia	039
Alsina, Mercè	038
Altuna, Ane	Z-07
Altunbulakli, Can	L-01, N-01
Amarov, Boyko	O-06
Amerio, Paolo	075
Amin, Sapna M.	049
Amitay-Laish, Iris	Y-01, Z-29
An, Bervoets	061
Andersen, Erica F.	O-01
Andrade Campos, Marcio	V-01
Andrade, Andrea	D-05
Andrades, Evelyn	R-01
Àngel Baldó, Joan	043
Angello, James	Y-02, Y-03
Angles, Valeria	D-05
Anne Catherine, Bretz	069
Anne, Boland	J-03

Anne, Pham-Ledard	O-02, O-03
Annemie, Rutten	061
Antoine, Martin	041
Anzengruber, Florian	O-06
Ara Martín, Mariano	045
Arai, Sally	U-01
Araiz, Maria	Z-07
Aranguren-López, Iñigo	050
Arenillas, Leonor	M-05
Arkin, Coral	K-03
Armand, Bensussan	J-03
Arregui-Murua, Maria Asuncion	Z-07, 050
Arrue Michelena, Itziar	047, 051
Arumainathan, Arvind	X-02
Aspe Unanue, Libe	033
Assaf, Chalid	H-01, Z-27, 002, 063
Audrey, Gros	O-02, O-03
Aung, Phyu	B-06
Azcona, Maialen	022
Azurdia, Richard	X-02

B

Bagot, Martine	B-01, B-02, C-01, C-02, D-01, I-01, T-01, X-01, Z-09, 008, 029, 073, 077
Baik, Sarah	J-04
Bailey, William	Y-03
Bakr, Farrah	S-02
Balaguer Franch, Inmaculada	068
Balazs, Zsolt	T-04
Baldasseroni, Lyla	K-02
Baldini, Luca	U-02
Baldo, Antonello	075
Baltás, Eszter	Z-05
Bar-Natan, Michal	L-02
Barrios, Estella	P-04
Barros Domingues, Regina	Z-26
Barta, Stefan	V-06
Bastidas Torres, Armando	N-03
Bastos Oreiro, Mariana	068, 079
Battistella, Maxime	B-01, B-02, C-01, C-02, I-01, T-01, Z-09, 008, 029, 073
Bauer, Andrea	Z-06
Bauer, Wolfgang	J-01
Béatrice, Vergier	O-02, O-03



Bechter, Oliver	V-05	Brown, Lisa	V-05
Becker, Jürgen C.	062	Bruey, Silvina	D-05
Beisel, Christian	T-04	Bruni, Pier Luigi	075
Bekkenk, Marcel	X-04, Z-08	Brunner, Patrick M.	J-01
Beksac, Burcu	J-04	Buelens, Odette	Z-25
Bellosillo, Beatriz	M-05, 020	Bunick, Christopher G.	Z-13
Beltraminelli, Helmut	B-01, B-02, 048	Bunn, Veronica	V-05
Bengoechea-Nerecan, Enrique	050	Bupha- Intr, Olivia	Z-25
Benoit, Bernice	W-02	Burlando, Martina	075
Bensussan, Armand	I-01, T-01	Busschots, Anne-Marie	C-01, C-02
Berg, Sara	V-06, W-02	Buus, Terkild B.	L-02, 062
Bergon Sendin, Marta	068, 079		
Bernd, Hemmerlein	Z-27	C	
Bernstein, Joel	070	Calderon Gutierrez, Maria Jose	034
Berti, Emilio	C-01, N-03, U-02, 075	Calvo, Xavier	M-05
Bertuzzi, Clara	025, 065	Calzavara Pinton, Piergiacomo	075
Beylot-Barry, Marie	C-01, K-02, T-01, 048	Campbell, Belinda A.	Z-25
Bhat, Trisha	P-02, P-03, P-05	Campbell, James	S-01
Bielsa, Isabel	V-01	Campo, Elias	003
Bigas, Anna	R-01	Campos-Dominguez, Minia	056
Binder, Gary	Y-02	Canal García, Elena	043
Blanch Rius, Laura	010	Cancho Galán, Goikoane	019, 021
Blanco, Gonzalo	L-04, R-01	Carlotti, Agnes	048
Błażewicz, Izabela	T-02	Carlson, Kacie R.	R-02, R-05, Z-13
Blümel, Edda	062	Carnero González, Lucia	033
Boggon, Titus J.	L-01	Carpentier, Olivier	048
Bohelay, Gerome	048	Carretero-Lopez, Fernando	079
Bohjanen, Kimberly	D-06, X-03	Carter, Joi	032
Boki, Hikari	027, 067	Casadei, Beatrice	025
Borbényi, Zita	Z-05	Casanova Seuma, Josep Manel	043
Borgmann, Matthias	S-05, 072	Casarin, Francesca	U-02
Borrego, Leopoldo	M-01	Cascante, Lourdes	022
Borregon, Jennifer	H-03	Cassoli Cortez, Anita	040
Bouaziz, Jean-David	Z-09	Castellvi, Josep	055
Bowen, Glen	017	Castro, Liza	007
Bowman, Anita S.	N-02	Caton Santaren, Blanca	047
Brammer, Jonathan	V-04	Cats, Davy	N-03
Braun, Jana Dorothea	001	Cayrol, Maria Florencia	S-04
Brazzelli, Valeria	075	Cayuela, Jean-Michel	T-01
Bretz, Anne Catherine	S-05	Cerchiatti, Leandro	S-04
Brice, Pauline	Z-09	Cereceda, Laura	H-03, M-04
Brito Pinheiro Ramos Santos, Sarah	006	Cerroni, Lorenzo	C-01, M-01, O-01
Britt M, Hermes	G-06	Chavda, Rajeev	077
Broccoli, Alessandro	025	Chebly, Alain	K-02

Cheng, Anthony	L-02	Daniels, Jay	L-01, N-01
Cheronis, Ioanna	071	Daniëls, Laurien	X-04
Chevret, Edith	K-02	Daruish, Maged	Z-20, Z-22
Child, Fiona	T-03, U-03, X-05	Davis, Michael	032
Choi, Jaehyuk	L-01, N-01, O-01, Z-02	Dawe, Robert S.	074
Choi, Sara	L-01	De Brito, Marianne	X-02
Chovatiya, Raj	Z-21	De Clippelé, Donatienne	029
Christina, Mitteldorf	Z-27	De Dios Velazquez, Alvaro	O-05
Christoph, Blazejak	002	De Francesco, Irene	X-05
Christophe, Battail	J-03	De Freire Cassia, Flavia	004, 005, 006, 007
Chung, Catherine G.	V-04, Y-04, Z-01, Z-18, 026	De Groen, Ruben A.I.	O-04
Ciepluch, Hanna	P-01	De Haard, Hans	T-01
Cintra, Maria Leticia	Z-12, Z-16	De Haas, Ellen	X-04
Clark, Rachael A.	W-02	De La Torre Gomar, Francisco Javier	033, 047, 051, 057
Claus-Detlev, Klemke	Z-27, 002	De Masson, Adèle	D-01, I-01, J-03, Z-09, 008, 029
Clémentine, Descours	036	De Melo Miranda, Vitor José	Z-10
Cleven, Arjen	Z-08	De Winne, Koen	T-01
Climent Esteller, Fina	B-02, Z-06	Dean, George	G-02, L-02
Colomo, Luis	M-05, 023, 046, 053	Deandreis, Desiree	073
Combalia, Andrea	003, 038, 039	Debernardi, Maria Mercedes	S-04
Comfere, Nneka I.	B-05	Defrancesco, Irene	T-03, U-03
Conde, David	R-01	Degasperi, Andrea	G-04
Conran, Carly	L-01	Del Guzzo, Christina	V-06, W-02, 009
Cooke, Anisha	R-03	Delahaye, Tim	T-01
Coolman, Tyler	078	Della Ripa Rodrigues Assis, Gabriela	Z-10, Z-12
Coralie, Zumelzu	041	Demeter, Judit	059
Córdoba, Alicia	022	Devaney, Alice	H-02
Córdoba, Raúl	M-01	Di Raimondo, Cosimo	K-04
Cortes, Jose	R-03	Dias Barbosa, Carla	077
Corti, Laura	N-03	Diaz Flaque, Maria Celeste	S-04
Cowan, Richard	C-01, C-02, X-02	Diepstra, Arjan	O-04
Cowper, Shawn	Z-13	Diercks, Gillis	Z-08
Cozzani, Emanuele	075	Dimitriou, Florentia	O-06, 073
Cozzio, Antonio	B-01, B-02, O-06, X-01	D'incan, Michel	036
Cremaschi, Graciela	S-04	Dorado Herrero, Nieves	068, 079
Csányi, Ildikó	Z-05	Doss, Gowardhanan	X-05
Csomor, Judit	058, 059	Doukas, Peter G.	L-01, N-01
Curatolo, Ann Marie	071	Downey, Camila	D-04
Curry, Jonathan	B-06	Drori, Avi	Z-29
Cury-Martins, Jade	C-04, V-03, Z-26, 063	Drori, Guy	Z-29
D			
Da Costa Llanos, Felipe	005	Dubois, Romain	048
Dalle, Stephane	T-01, V-05	Dummer, Reinhard	O-06, T-04, V-05
Damoraki, Georgia	064		
Danhauser-Riedl, Susanne	072		

Dunnill, Giles	X-02
Duran, Xavier	020
Durlac, Anne	048
Durot, Eric	048
Duvic, Madeleine	B-01, B-02, B-05, B-06, V-05

E

El-Afifi, Amal	Z-22
El-Lithy, Mahmoud	Z-22
Elodie, Bohers	O-03
El-Sayed, Mahira Hamdy	Z-22
El-Tayeb, Nada	Z-22
El-Zawahry, Khaled	Z-20
El-Zimaity, Maha	Z-22
Enciso Olivera, Leonardo J	076
Enz, Paula	D-05
Eradat, Herbert	V-05
Eric, Frison	O-02, O-03
Escolar, Diana M.	071
Espinet, Blanca	L-04
Espinosa, Lluís	R-01
Espinosa, Maria L.	B-04, B-05, Z-02, 049
Espinoza-Benavides, Leonardo	Z-15
Estrach, Teresa	C-01, L-04, M-01, 003, 038, 039
Eve, Maubec	041
Evison, Felicity	C-01, C-02, X-01

F

Fabrice, Jardin	O-02, O-03
Fajnerman Tel-Dan, Shira	C-03
Fanok, Melania	G-02
Fanoni, Daniele	N-03, U-02
Fantelli Stelini, Rafael	Z-10, Z-12, Z-16, Z-24, 028, 040
Fargnoli, Maria Concetta	075
Farlik, Matthias	J-01
Farouk, Mohamed	Z-14
Farquharson, Nina	X-02
Fatsini Blanch, Vanesa	057
Fernandes Pinheiro, Livia Stefania	007
Fernández Armenteros, Josep Manel	043
Fernandez, Concepcion	M-05
Ferrando, Adolfo	R-03

Ferreira Magalhães, Renata	Z-16, Z-24, 028
Ferrer, Ana	020
Ferrer, Berta	M-01, 055
Ferrer, Jacky	K-02
Fezatte, Heidi	070
Fisher, David	V-05
Flanagan, Charlotte E.	R-04
Florell, Scott	017
Florent, Grange	036
Fong, Sophia	W-03
Fornons, Rosa	Z-06
Foss, Francine	R-02, R-05, U-04, 071
Frank, Nathalie	048
Freeman, Kirsty	T-03
Frigola, Gerard	003
Fujii, Kazuyasu	052
Fulmer, Yi	G-02
Furtado, Michelle	X-02

G

Gabor, Dobos	D-01, J-03, Z-09, 029
Gabriel, Sylvie	077
Gainza Apraiz, Isabel	010, 019, 030
Gallardo, Fernando	L-04, M-05, R-01, V-01, 020, 023, 046, 053,
Gallop-Evans, Eve	X-02
Gambini, Daniele	075
Gandini, Domenica	T-01
Gantchev, Jennifer	018
Gao, Crytal	035
García Piqueras, Paloma	068
García Río, Irene	033
García Solano, Maria	O-05
García Toro, Enrique	M-01
García, Candelaria	M-01
García-Colmenero, Lidia	R-01
García-Herrera, Adriana	003, 038, 039
García-Muret, M. Pilar	L-04, 016
García-Patos, Vicente	055
Geller, Shamir	C-03, I-02, N-02
Georgiou, Elisavet	F-03, 024
Geskin, Larisa	B-01, B-02, G-01, G-02, L-02, R-03, V-05, X-01, Y-03
Giefing, Maciej	K-01
Gilmore, Elaine S.	Y-04, 026
Gimeno Castillo, Javier	033, 047, 051, 057



Ginhoux, Florent	I-01	Guitart, Joan	B-01, B-02, B-04, B-05, L-01, N-01, O-01, Y-03, Z-02, Z-21, 049
Giordano, María Consuelo	D-04	Gundula, Streubel	069
Girardi, Michael	D-02, R-02, R-05, U-04, Y-03, Z-13	Gunes, E. Gulsen	E-01, S-06
Givskov, Michael	062	Gurbity Pálfi, Tímea	Z-05
Giza, Agnieszka	P-01, Z-19	H	
Gjerdrum, Lise M. R.	062	Habib, Zouali	J-03
Glazko, Galina	L-03, 060	Hahtola, Sonja	081
Gliozzo, Jessica	N-03	Halbritter, Florian	J-01
Gniadecki, Robert	014, 015	Halwani, Ahmad S.	017
Goerdts, Sergij	001	Hamada, Toshihisa	044
Goldaniga, Maria	U-02	Hamm, Svetlana	S-05
Goldberg, Ilan	C-03	Han, Dan	S-01
Goldman- Mazur, Sarah	Z-19	Hannah, Kallus	S-05
Gomez Bringas, Cristina	034	Haralambieva, Eugenia	073
Gómez Muga, Susana	010	Harkins, Shannon	O-01
Gómez-Llonín, Andrea	L-04	Hatanaka, Miho	052
González Del Tánago	019	Haun, Paul	B-01, B-02, V-06, 080
Diago, Jaime		Haverkos, Bradley	Y-02
González Núñez, María Ángeles	M-01	Hennessey, Dylan	014, 015
González Pérez, Ricardo	033, 051, 057	Henri, Adamski	036
González Romero, Nerea	010, 030, 034	Heras González, Sonia	057
Gonzalez, Jessica	R-01	Herbosa, Christina	P-02, P-03, P-05
González, Sergio	D-04, Z-11, Z-15	Hernandez De La Torre	068
González-Barca, Eva M.	Z-06	Díaz, Elisa	
González-Pérez, Ricardo	047	Herpers, Bjorn	062
Gorovitz, Batia	K-03, Z-29	Herrera, Alberto	G-02, L-02
Goula Fernández, Sofia	051	Hideghéty, Katalin	Z-05
Gowda, Lohith	U-04	Higashi, Yuko	052
Gowthaman, Ragul	N-01	Hiniker, Susan	W-03
Goyal, Amrita	D-06, X-03, Z-23, 011	Hirotsu, Kelsey E.	X-06, X-07
Grandi, Vieri	G-04, H-02, U-03, X-05, 042, 075	Ho, Caleb	I-02, N-02
Grange, Florent	048	Hodak, Emily	X-01
Grekova, Ekaterina	I-03, 012	Hodak, Emmilia	B-01, B-02, C-01, C-02, K-03, Y-01, Z-29
Grifoni, Federica	U-02	Holdich, Alexandra	S-02
Grillo Ruggieri, Filippo	U-02	Holton, Joseph	080
Gru, Alejandro	B-01, B-02, C-01, N-01	Honda, Kord	M-03
Gruber, Aurélie	008	Hong, Bo	O-01
Gu, Yuhan	R-03	Hong, Eric	C-01, C-02, W-03
Guenova-Hotzenecker, Emmanuella	B-01, B-02, C-01, O-06, 073	Hoppe, Richard T.	U-01, W-03
Guggenberger, Roman	073	Horvath, Barbara	X-04
Guggina, Lauren	Z-21	Horwitz, Steven	B-05, I-02, N-02, V-05, X-01, 037
Guglielmo, Alba	025, 065	Howard, Olivia	078



Hsu, Daniel	S-01
Huang, Ying	V-04
Huen, Auris	B-06
Hughes, Simon	073
Hultberg, Anna	T-01
Huson, Bérengère	048
Huynh, Mindy	S-01
Hwang, Sam	E-03, R-06, S-01
Hymes, Kenneth	G-02, L-02

I

Iacovelli, Paolo	075
Ibrahim, Mona Abdel-Halim	Z-14, Z-20, Z-22, Z-28, 013
Idrissi, Yamina	K-02
Iglesias, Arnau	R-01
Iriondo, June	Z-07
Ispizua Mendivil, Estibaliz	030
Isufi, Iris	U-04
Iversen, Lars	062
Iwatsuki, Keijii	044
Iyer, Aishwarya	014, 015
Iznardo, Helena	016
Izu Belloso, Rosa María	010, 019, 021, 030, 034
Iżykowska, Katarzyna	K-01

J

James, Eleanor	X-02
Jan P., Nicolay	H-01, Z-27, 002
Jana, Braun	H-01
Janakarim, Murali	071
Janela, Baptiste	I-01
Jansen, Patty	B-03, O-04, X-04, Z-08
Jariwala, Neha	V-06, W-02
Jayaprakash, Sindoor	X-02
Jean-François, Deleuze	J-03
Jean-Philippe, Merlio	O-02, O-03
Jeffe, Donna	P-03
Jeroen, Pyl	061
Joanna, Olk	002
Johansen, Claus	062
John F, Baines	G-06
Johnson, Amy	V-04, Z-01, Z-18
Johnson, Courtney	D-03
Johnson, Lisa	E-03
Jonak, Constanze	C-02, J-01
Jońca, Marcin	Z-19

Jones, Christine L.	G-04, H-02, R-04, S-02
Jones, Emma	T-03
Jonsson, Vanessa	S-06
Jost, Marion	054
Jothishankar, Balaji	L-01, N-01
Jouenne, Fanélie	008
Jo-Velasco, Margarita	O-05
Joyce, Robin	71
Juliá Manresa, Marc	021
Junkins-Hopkins, Jacqueline	B-01, B-02
Jürgen, Harder	G-06

K

Kadin, Marshall E.	F-01, G-02, L-02
Kamijo, Hiroaki	G-05, 027, 066, 067
Kanekura, Takuro	052
Kanfer, Edward	U-03
Kawana, Yuki	027
Kemény, Lajos	Z-05
Kempfer, Werner	B-01, B-02, C-01
Kerstin, Kronthaler	069
Keto, Jaana	081
Khalid, Amina	074
Khodadoust, Michael S.	J-02, U-01, W-03
Khuong-Quang, Dong-Anh	M-02
Kilian, Mogens	062
Kim, Ellen	V-06, W-02, Y-03, 080
Kim, Sa Rang	R-02, R-05
Kim, Youn H.	B-01, B-02, B-05, C-01, C-02, J-02, U-01, V-05, W-03, X-01, X-06, X-07
King, Amber Loren O.	R-02, R-05
King, Brett	Z-13
Knaneh, Jamal	K-03
Knobler, Robert	B-01, B-02, C-01
Koletsas, Triantafyllia	F-03, 024
Koltai, Hinanit	Z-29
Koralov, Sergei	G-01, G-02, L-02
Kosa Lino Duarte, Bruno	040
Koufargyris, Panagiotis	064
Kouttab, Nick	F-01
Kovalchuk, Sofia	042
Krammer, Peter H.	001
Krauthammer, Michael	T-04
Krejsgaard, Thorbjørn	062



Krenács, László	Z-05
Kronthaler, Kerstin	S-05
Kruglov, Oleg	E-03, R-06, W-01
Kumar, Erica S.	B-05
Kwok, Pui-Yan	L-01
Kwong, Bernice Y.	X-06, X-07

L

Lacasta Plasin, Clara	068
Laggis, Caroline	017
Laird, Mary	G-02
Lamb, Andrew	017
Landsburg, Daniel	V-06
Lansigan, Frederick	032
Laroche, Liliane	048
Lastrucci, Irene	042
Latkowski, Jo-Ann	G-02, L-02
Laurence, Michel	J-03
Lazaridou, Elizabeth	F-03, 024
Lázaro Serrano, Mireya	019
Lazaryan, Aleksandr	011
Lebbé, Céleste	008
Le Clech, Christian	048
Leupin, Nicolas	T-01
Levesque, Mitchell Paul	T-04
Lewis, Daniel	V-06, W-02
Lewis, Julia M.	R-02, R-05, Z-13
Li, Shufeng	W-03
Liliane, Laroche	041
Limeres Gonzalez, Miguel Ángel	M-01
Lindahl, Lise Marie	062
Linna, Miika	081
Linos, Konstantinos	032
Lisano, Julie	V-05
Litman, Thomas	062
Little, Meredith	V-05
Litvinov, Ivan	018
Llobera, Clàudia	Z-06
Lobato Izagirre, Ane	019, 021, 034
Lobo, Carmen	M-01
Lombardi, Clara	Z-07
Longo, Caterina	075
Lopert, Pamela	071
Lopes Iori, Nathalia	Z-12, 040
López Aventín, Daniel	L-04, 020

Lopez, Arantxa	Z-07
Lopez-Lerma, Ingrid	L-04, V-01, 055
López-Pestaña, Arantxa	050
López-Sánchez, Cristina	016
López-Sánchez, Manuela	L-04
Loscalzo, Matthew	P-04
Louissaint Jr., Abner	L-01, N-01, O-01
Lubin, Ido	Z-29

M

Machado De Moraes, Aparecida	Z-10
Machado Toribio, Jaqueline	Z-24
Machan, Salma	H-03, M-01, O-05
Machet, Laurent	048
Mackey, Adam	R-03
Maerevoet, Marie	T-01
Magro, Cynthia	S-04
Maio, Vincenza	042
Maity, Amit	W-02
Mangar, Steven	U-03
Mangold, Aaron R.	B-05
Manso Aonso, Rebeca	H-03, M-01, M-04
Mansukhani, Sonal	077
Marie, Beylot-Barry	O-02, O-03, 036
Marie, Parrens	O-02
Marie-Cardine, Anne	I-01, T-01
Marion, Jost	G-06
Marion, Wobser	H-01, Z-27, 002
Mariscal Polo, Amaya	021
Marquez Navarro, Jose Antonio	034
Marschalkó, Márta	C-01, Z-05, 058, 059
Marschalko, Martha	C-02
Marshall, William S.	071
Martí Laborda, Rosa Maria	043
Martin, Rubeta	C-02
Martine, Bagot	J-03, 036
Martínez De Lagrán	033, 047, 051, 057
Álvarez De Arcaya, Zuriñe	
Martinez Escala, Maria	N-01
Martínez Villarreal, Amelia	018
Martinez, Xochiquetzal	P-04, 082
Martínez-Aracil, Álvaro Pérez	057
Martinez-Escala, Maria Estela	B-04, B-05, L-01, O-01, Z-02, 049

Martínez-González, María Isabel	047	Molgó, Montserrat	D-04, Z-11, Z-15
Mary, Wain	U-03	Molinelli, Elisa	075
Massuda Serrano, Juliana Yumi	Z-10, Z-12, Z-16, Z-24, 028, 040	Monfrecola, Giuseppe	075
Mateos-Mayo, Ana	056, 068	Monteagudo, Carlos	M-01
Matin, Rubeta	C-01	Montenegro, Társila	M-01
Matteo, Elena	O-05	Morgan, Elizabeth A.	O-01
Matthias, Borgmann	069	Morgan, John	F-01
Max, Schlaak	H-01	Morimura, Sohshi	G-05
Mazuz, Moran	Z-29	Morizane, Shin	044
Mccormack, Christopher	M-02, Z-25, 035	Morris, Stephan	X-05
McDonald, Ryan	071	Morris, Stephen	T-03, U-03
Mcniff, Jennifer	Z-13	Morschhauser, Franck	T-01
Medhi, Syed Jafar	E-02, L-03	Moshir, Mahan	T-01
Mehmet, Baltaci	Z-27	Moskowitz, Alison	I-02, Z-04, 037, 071
Mehta-Shah, Neha	P-02, P-03, P-05	Mostafa, Ahmed	Z-22
Mei, Hailiang	N-03	Motolese, Alberto	075
Melchers, Rutger	X-04, Z-08	Motta, Giovanna	T-01
Melle, Federica	T-01	Mourah, Samia	008
Menarguez Palanca, Javier	068	Moy, Andrea P.	O-01
Mendivil, Begoña	Z-07	Moyal, Lilach	K-03, Z-29
Menzel, Ulrike	T-04	Mozos, Ana	016
Merkel, Emily	Z-21	Mozzicafreddo, Giorgio	075
Merlio, Jean-Philippe	K-02	Mühleisen, Beda	O-06
Meruelo Ruano, Mikel	021, 030, 034	Muniesa, Cristina	V-01, Z-06
Michel, Laurence	Z-09, 029	Muro, Manuel	L-04
Michel, Mirna	Z-14, Z-22, 013	Musette, Philippe	I-01
Michelena, Miren Josune	022	Musiek, Amy	P-02, P-03, P-05, Y-03
Michot, Jean-Marie	T-01	Myskowski, Patricia L.	I-02, N-02, Z-04, 037
Miles, Rodney	017	N	
Mimitou, Eleni	L-02	Nacagami Sotto, Mirian	063
Mink, David	Y-03	Nagarajan, Priyadharsini	B-06
Miotto, Isadora	063	Nagy, Zsolt	059
Miranda, Roberto	B-06	Najidh, Safa	G-03
Mirhadi, Sara	073	Nakagawa, Yuki	044
Mirza, Fatima N.	D-02, R-02, R-05, Z-13	Nakajima, Rina	066
Mitchell, Tracey J.	G-04, H-02, R-04, S-02	Namdar, Dvora	Z-29
Mitteldorf, Christina	B-01, B-02, C-01, C-02	Nassar, Ahmed	Z-22, Z-28, 013
Miyagaki, Tomomitsu	G-05, 027, 066, 067	Nasta, Sunita	V-06
Miyashiro, Denis	C-04, V-03, Z-26, 063	Navarini, Alexander	O-06
Mo, Samuel H.	N-01	Navarrete-Viveros, Jesus	B-06
Moerman-Herzog, Andrea	E-02, L-03, 060	Neal, Tatiana M.	X-06, X-07
Mohamed, Abdelrahman	Z-22	Neder Ramires Abdo, Andre	V-03, Z-26
Mohanad, Aljundi	041	Ngu, Ivy	X-02
Moins-Teisserenc, Hélène	T-01	Nguyen, Morgan T.	Z-02
		Nicolas, Faur	O-03



Nicolay, Jan P.	001
Nieto-Benito, Lula Maria	056, 068, 079
Nikbakht, Neda	J-04, V-02
Nik-Zainal, Serena	G-04
Nobre, Aretha	007
Noor, Sarah	I-02, Z-04, 037
Nowica, Karina	K-01
Nunes Secamilli, Elisa	Z-10, Z-12, Z-16, Z-24, 028, 040

O

Océane, Ducharme	O-03
Ócsai, Henriette	Z-05
O'donnell, Megan	J-04, V-02
Odum, Niels	G-02, L-02, 062
Offidani, Anna Maria	075
Offner, Fritz	T-01
Ogueta, Isabel	Z-11
Oka, Tomonori	G-05, 066, 067
O'keefe, Sandra	014, 015
Oláh, Judit	Z-05
O'leary, Daniel	X-03, 011
Olek-Hrab, Karolina	K-01
Olisova, Olga	I-03, 012
Olmedilla, Gabriel	045
Olmos, Ferran	053
Olszewska, Berenika	T-02
Ondarra, Laida	Z-07
Onida, Francesco	U-02
Orlovius, Martin	072
Ortiz Romero, Pablo L.	B-01, B-02, C-01, V-05, X-01
Ortonne, Nicolas	048
Oschlies, Ilske	054
Ouyang, Zhengqing	L-02

P

Pacheco, Theresa	Y-02
Pacifico, Alessia	075
Paczkowska, Julia	K-01
Pajares, Raquel	M-04
Palanca-Wessels, Maria Corinna	V-05
Palanicawandar, Renuka	U-03
Palmer, Joycelynne	P-04
Palomar Moreno, Carmen Irene	H-03
Palomero, Teresa	R-03
Papadaki, Marianna	064

Papadavid, Evangelia	B-01, B-02, C-01, C-02, X-01, 064
Papaleo, Natalia	M-05, 023, 053
Papathemeli, Despoina	F-03, 024
Parekh, Vishwas	M-03
Parente Almeida, Isabella	Z-26
Park, Joonhee	L-01, N-01
Park, Katherine E.	B-05
Parnitzke, Ulrike	S-05
Parodi, Aurora	075
Parra Blanco, Veronica	056, 068
Parry, Eileen	X-02
Pascal, Joly	036
Patel, Varsha M.	R-04
Patino, Patricia	W-01
Patrizi, Annalisa	025, 065
Patrone, Christina	R-03
Patsatsi, Aikaterini	F-03, 024
Patterson, Jordan	014, 015
Paulli, Marco	N-03
Pauwels, Patrick	T-01
Paxton, Christian N.	O-01
Pearson, David	D-06
Pease, David R.	L-01, N-01
Pellegrino, Michele	075
Pereira Quintella, Leonardo	006
Pereira, Juliana	C-04, V-03, Z-26, 063
Pérez Manich, Juliette	043
Pérez Parrio, Silvia	019
Perez, Nuria	H-03
Perez-Ferriols, Amparo	V-01
Pestano, Linda A.	071
Pham-Ledard, Anne	K-02
Philippe, Ruminy	O-02
Phillip, Jude M.	S-04
Phillips, Adrienne	071
Phillips, Scott	070
Piątkowska- Jakubas, Beata	Z-19
Piccinno, Roberta	075
Pierce, Brian G.	N-01
Pierre-Julien, Viailly	O-03
Pigatto, Paolo	075
Pigem, Ramon	039
Pikou, Olga	F-03, 024
Pileri, Alessandro	025, 065, 075



Pileri, Stefano	T-01	Ram-Wolff, Caroline	D-01, Z-09, 008, 029, 073, 048
Pimpinelli, Nicola	C-01, 042, 075	Rao, Deepak	L-01
Pincus, Laura	B-05, Z-02	Rassek, Karolina	K-01
Pineiro-Maceira, Juan Manuel	004	Ražny, Małgorzata	Z-19
Pinter-Brown, Lauren	V-05, 071	Reimann, Philip	072
Piperi, Christina	064	Ren, Rongqin Ren	Z-01, Z-18
Piris Pinilla, Miguel Ángel	H-03, M-01, M-04, O-05, 045	René, Stranzenbach	H-01, Z-27, 002
Podkowik, Magdalena	G-02	Reneau, John	V-04
Poglio, Sandrine	K-02	Requena Caballero, Luis	M-01, O-05
Poligone, Brian	Y-02, Y-04, Z-03, 026	Revuelta, Maria Victoria	S-04
Pontes, David	Z-02	Reyes-Baraona, Francisco	D-04, Z-11
Porcu, Pierluigi	J-04, V-02, X-01	Ribrag, Vincent	T-01
Porkert, Stefanie	J-01	Rieger, Kerri E.	B-05, X-06, X-07
Prag Naveh, Hadas	Y-01	Riera-Monroig, Josep	003, 038, 039
Priebe, Waldemar	T-02	Ringbloom, Kimberly G.	L-01, N-01, O-01
Prieto Torres, Lucia	M-04, 045	Rivet, Jaqueline	Z-09, 008
Prieto, Victor	B-06	Robert, Knobler	072
Prince, Henry Miles	C-01, V-05, X-01, Z-25	Roberts, Ken	U-04
Pro, Barbara	L-01, N-01, Z-02, Z-21	Robson, Alistair	B-01, B-02
Prochazkova-Carlotti, Martina	K-02	Rodríguez Moreno, Marta	M-01
Przybylski, Grzegorz	K-01	Rodríguez Pinilla, Socorro María	H-03, M-01, M-04, O-05, 045
Puelles, Jorge	077	Rodriguez, Eva	R-01
Puig, Lluís	016	Rodriguez-Lomba, Enrique	056
Puiggros, Anna	L-04	Rodríguez-Peralto, Jose Luis	M-01
Pujol Vallverdú, Ramón M.	C-02, L-04, M-05, R-01, 020, 023, 046, 053	Rojas, Patricio	Z-15
Pulido-Perez, Ana	056, 068, 079	Roland, Schneiderbauer	Z-27
Pulitzer, Melissa	B-01, B-02, B-05, I-02, N-02, Z-04, 037	Romero-Jimenez, Rosa	079
Pullion, Christopher	Z-03	Roncador, Giovanna	065
Putter, Hein	X-04	Rook, Alain H.	V-06, W-02, 009, 080
Q			
Quaglino, Pietro	B-01, B-02, C-01, V-05, X-01, 072, 073, 075	Rook, Bathanie	B-02
Querfeld, Christiane	B-01, B-02, C-01, C-02, E-01, K-04, M-03, P-04, S-06, Y-02, Y-03, 071, 082	Rooke, Bethanie	B-01, X-02
Quinn, S. Aidan	R-03	Ropio, Joana	K-02
Quint, Koen D.	B-03, O-04, X-04, Z-08	Rosell Díaz, Angel Manuel	056, 068, 079
R			
Rabionet, Raquel	L-04	Rosen, Steve T.	E-01, K-04, M-03, P-04, S-06, 082
Rahmatallah, Yasir	L-03, 060	Rosenberg, Abby	P-02, P-03, P-05
Ramelyte, Egle	T-04	Rosenthal, Jaclyn M.	080
Ramos, Juan	071	Roses Gibert, Pau	033, 047, 051, 057
		Roshal, Mikhail	I-02
		Rovira-López, Roger	023, 046
		Rozati, Sima	D-03
		Ruan, Jia	S-04
		Rubin, Paul	071



Rudolf, Stadler H-01, 002
 Rueda, Xavier 076
 Rupoli, Serena 075
 Rytenband, Fernanda 028, 040

S

Sabattini, Elena 025, 065
 Sabine, Brechignac 041
 Sacha, Tomasz Z-19
 Sadoux, Aurélie 008
 Sáenz Aguirre, Amaia 033, 047, 051, 057
 Sagasta Lacalle, Amaia 051
 Sahni, Nidhi L-01, N-01
 Salar, Antonio V-01
 Samimi, Sara V-06, 080
 Samuel, Samira H-02
 Sanches Jr, Jose Antonio B-01, B-02, C-04, V-03,
 V-05, Z-26, 063
 Sánchez Díez, Ana 010
 Sánchez Frías, Marina
 Esther O-05
 Sanchez Herrero, Alejandro 068
 Sanchez Martin, Marta R-03
 Sanchez, Blanca V-01
 Sanchez-Herrero,
 Alejandro 056
 Sanders, Cornelus X-04
 Santucci, Marco 042
 Saporiti, Giorgia U-02
 Sara, Laurent Roussel 041
 Sarah, Ivanoff 041
 Sarah, Menguy O-02
 Saraki, Konstantina 064
 Sarja, Stendel Z-27, 002
 Saskia, Oro 036
 Sato, Shinichi G-05, 027, 066, 067
 Saulite, Ieva O-06
 Savoia, Paola 075
 Scarisbrick, Julia B-01, B-02, C-01, C-02,
 V-05, X-01, X-02, 072, 073
 Scher, Jose G-02
 Schiavone, Concetta U-02
 Schrader, Anne M.R. O-04
 Schroeder, Kristin M. S. 071
 Schuster, Stephen V-06
 Secrest, Aaron 017
 Seffens, Angelina G-01, G-02, L-02

Segal, Leopoldo G-02
 Segues, Nerea Z-07
 Selli, Mehmet E. N-01
 Semenov, Yevgeniy P-02, P-03, P-05
 Sergij, Goerd H-01
 Seropian, Stuart U-04
 Servitige, O. C-02
 Servitje, Octavio C-01, L-04, V-01, Z-06
 Shaw, Lisa J-01
 Shea, Christopher N-01
 Shi, Zhenrui S-01
 Shih, David J.H. L-01, N-01
 Shimauchi, Takatoshi F-04
 Shinohara, Michi 078
 Shono, Yuki 067
 Shopsin, Bo G-02
 Sigues, Nerea M-01
 Silberman, Sandra T-02
 Silence, Karen T-01
 Silva-Carmona, Mary Yohana Z-07, 050
 Silverberg, Jonathan I. Z-02
 Sim, Van Ren T-03
 Simonacci, Marco 075
 Simontacchi, Gabriele 042
 Singh, Rajinder S-01
 Slavin, Monica Z-25
 Smibert, Peter L-02
 Smirnov, Konstantin 012
 Soares, Paula K-02
 Sokołowska-Wojdyło,
 Małgorzata P-01, T-02
 Solar, Irit C-03
 Solleveld, Nienke Z-08
 Song, Joo M-03
 Sonigo, Gabrielle I-01
 Sophie, Ly Ka So J-03
 Soria Gili, Xavier 043
 Souza, Elemir Macedo Z-16
 Sprecher, Eli C-03
 Stadler, Rudolf B-01, B-02, C-01, V-05,
 X-01, Z-17, 072
 Stalin, Rajan N. Z-29
 Stehr, Henning J-02
 Stéphane, Dalle 036
 Stien, Sarah 048
 Stiller, Tracey P-04



Stoll, Joseph	Z-04, 037
Stracht, Teresa	V-01
Streubel, Gundula	S-05
Suarez-Fernandez, Ricardo	068, 079
Subtil, Antonio	B-01, B-02
Suga, Hiraku	G-05, 027, 066, 067
Sugaya, Makoto	G-05, 027, 066, 067
Sun, Amy	L-02
Suzuki, Natalia Naomi	028
Sven, Schneider	H-01
Svetlana, Hamm	069
Svoboda, Jakub	V-06
Szakonyi, József	058, 059
Szepesi, Ágota	058, 059

T

Tabanelli, Valentina	T-01
Takahashi, Takahide	044
Takahashi-Shishido, Naomi	G-05, 066
Tan, Timothy	B-04
Tanja, Wulff	069
Tao, Randa	017
Tastanova, Aizhan	T-04
Tatsuno, Kazuki	F-04
Taylor, Kerry	V-05
Teague, Jessica E.	W-02
Tegla, Cosmin	G-02, L-02
Tegtmeyer, Kyle	L-01, N-01
Teh, Benjamin	Z-25
Tensen, Cornelis P.	C-03, N-03
Tetzlaff, Michael	B-06
Thilo, Gambichler	002
Thomas, Bandres	O-03
Thomas, Jane J.	L-01, N-01
Thonnart, Nicolas	I-01
Thornton, Susan	077
Thorsten, Braun	041
Thursky, Karin	Z-25
Tiroler, Amir	Z-29
Tokura, Yoshiki	F-04
Tomb, Roland	K-02
Toquica, Alejandra	076
Torres Cabala, Carlos A.	B-01, B-02, B-05, B-06
Torres, Ángeles	M-01

Torres, Victor	G-02
Trager, Megan	Z-09, 029
Trascasa, Alvaro	045
Trébol Urrea, Izaskun	033
Trotman, Judith	V-05
Trovato, Emanuele	075
Tsang, Mathew	018
Turko, Patrick	T-04
Twigger, Robert	Z-25

U

Ufkes, Nicole	017
Uger, Robert	E-03
Ulrike, Parnitzke	069
Urigoitia Ugalde, Peru	030
Urraca, Jose Maria	Z-07
Urtaran Ibarzábal, Amaia	051
Uwe, Hillen	Z-27

V

Vakeva, Liisa	C-01, 081
Valentine, Jake	Z-25
Valli, Viviana	U-02
Van Cauwenberghe, Owen	Z-29
Van De Loo, Merel	Z-08
Van Den Berg, Anke	O-04
Van Der Sluijs-Gelling, A.J.	G-03
Van Der Weyden, Carrie	Z-25
Van Dongen, J.J.M.	G-03
Van Hall, Thorbald	G-03
Van Kester, Marloes	Z-08
Van Rompaey, Luc	T-01
Van Rossum, Michelle	X-04
Van Santen, Suzanne	B-03
Van Wezel, Tom	O-04
Varga, Erika	Z-05
Vasiliki, Siozopoulou	061
Vazquez, Ivonne	M-05, 023, 053
Venturini, Marina	075
Veraart, Joep	X-04
Vercellino, Laetitia	073
Vergier, Beatrice	048
Vermaat, Joost S.P.	O-04, X-04
Vermeer, Maarten H.	B-03, C-01, G-03, N-03, O-04, X-01, X-04, Z-08
Vignon-Pennamen, Marie-Dominique	Z-09, 008, 029



Vilardell Vilellas, Felip	043
Villasenor-Park, Jennifer	V-06, 080
Visentainer, Lorena	Z-10
Vittorio, Carmela	V-06, W-02, 080
Vivanco Allende, Blanca	O-05
Vízkeleti, Júlia	058
Volonteri, Victoria	D-05

W

Wachsmuth, Rachel	X-02
Wada, David	017
Wain, Mary	T-03, X-05
Walewski, Jan	V-05
Walker, Christina J.	B-04, B-05, Z-02, 049
Walton, Kara E.	049
Wang, Erica B.	J-02, W-03
Wang, Jennifer Y.	X-06, X-07
Wang, Weiwei	014, 015
Wang, Yang	F-01
Weatherhead, Sophie	X-02
Wehkamp, Ulrike	C-01, C-02, G-06, H-01, Z-27, 002, 054, 063
Weichenthal, Michael	V-05
Weinstock, David M.	O-01
Weng, Wen-Kai	U-01
Wenzel, Alexander	O-01
Werner, Kempf	Z-27
Whittaker, Sean J.	C-01, G-04, H-02, R-04, S-02, T-03, U-03, V-05, X-05
Wilk, Mateusz	Z-19
Willemze, Rein	B-03, C-01, N-03, O-04, X-01, X-04, Z-08
Willerslew-Olsen, Andreas	062
William, Basem	V-04, Z-01, Z-18
Williams, Michael	Y-03
Williams, Paul J.	071
Wilson, Lynn D.	U-04
Wobser, Marion	C-01
Woetmann, Anders	062
Wong, Gane	014, 015
Wong, Henry K.	E-02, L-03, 060
Wong, Mark	E-03
Wu Yang, Ana Yi-Shi	M-04
Wu, Xiwei	K-04, S-06
Wu, Xuesong	E-03, R-06, S-01
Wulff, Tanja	S-05
Wysocka, Maria	W-02

X

Xu, Haiying	F-01
-------------	------

Y

Yang, Jingyi	L-01, N-01, O-01
Yanguas, Ignacio	022
Yoo, Jinah	C-02, X-02, 073
Yu, Sebastian	S-01
Yumeen, Sara	D-02, R-02, R-05, Z-13

Z

Zabrocki, Piotr	T-01
Zain, Jasmine	K-04, M-03, P-04, 071, 082
Zak, Ewa	T-02
Zaldua Arrese, Miguel	021
Zaletae, Dmitry	I-03
Zamponi, Nahuel	S-04
Zaya, Romsin	V-02
Zeberio-Etxetxipia, Izaskun	Z-07, 050
Zehir, Ahmet	N-02
Zehnder, Mara	O-06
Zhang, Chunlei	S-03
Zhang, Kevin K.	W-02
Zhang, Yancong	L-01
Zhou, Xiaolong	O-01, Z-21, Z-02
Zhou, Yan	S-01
Zic, John	B-01, B-02
Zidan, Omri	Y-01
Zimowska-Curyło, Dagmara	Z-19
Zinzani, Pier Luigi	T-01, V-05, 025
Zoutman, Willem H.	G-03
Zubizarreta-Salvador, José	050
Zumalde, Amaia	Z-07
Żurawek, Magdalena	K-01
Zwanenpoel, Karen	T-01

clonoSEQ®

NGS MRD

Revealing the
unseen¹



Sensitive.²

Detects a single cancer cell among a million healthy cells given sufficient sample input.

Specific.²

Enables identification and tracking of individual cancer cells.

Standardized.²

Extensive analytical and clinical validation.

The clonoSEQ Assay B-Cell Reagent Set is CE marked as in vitro diagnostic (IVD) for assessing the MRD status and changes in disease burden during and after treatment in B-cell malignancies in DNA extracted from blood and/or bone marrow samples.

1. Wood B, et al. *Blood*. 2018; 131(12):1350-1359.


2. clonoSEQ® Assay B-cell Reagent Set Instructions for Use. Seattle, WA; Adaptive Biotechnologies Corporation. 2018. Copyright © 2020 Adaptive Biotechnologies Corp. All rights reserved. PM-ES—0002

Specific skin-directed treatment



for
MF-CTCL

The first approved topical chemotherapy gel for MF-CTCL, proven for use from the early stages¹



Specifically MF-CTCL

1. LEDAGA SmPC. April 2019. | **Abbreviated Prescribing Information:** Ledaga® (chlormethine) **Important note:** Before prescribing, consult the full Summary of Product Characteristics (SmPC). **Presentation:** Chlormethine - 160 microgram/g gel. **Pharmacotherapeutic group:** Antineoplastic agents, nitrogen mustard analogues. **ATC code:** L01AA05. **Therapeutic indication:** Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF type CTCL) in adult patients. Posology and method of administration. Treatment with Ledaga should be initiated by an appropriately experienced physician. **Posology:** a thin film of Ledaga should be applied once daily to affected areas of the skin. The treatment should be stopped for any grade of skin ulceration or blistering, or moderately severe or severe dermatitis. Upon improvement, treatment with Ledaga can be restarted at a reduced frequency of once every 3 days. If reintroduction of treatment is tolerated for at least 1 week, the frequency of application can be increased to every other day for at least 1 week and then to once daily application if tolerated. **Method of use:** Patients must wash hands thoroughly with soap and water immediately after handling or applying Ledaga. Patients should apply Ledaga to affected areas of the skin. In case of Ledaga exposure to non-affected areas of the skin, patients should wash the exposed area with soap and water. Caregivers must wear disposable nitrile gloves when applying Ledaga to patients. Caregivers should remove gloves carefully (turning them inside out during the removal to avoid contact with Ledaga) and wash hands thoroughly with soap and water after removal of gloves. If there is accidental skin exposure to Ledaga, caregivers must immediately wash exposed areas thoroughly with soap and water for at least 15 minutes. Remove and wash contaminated clothing. The opening of the tube is covered with a foil safety seal. The cap should be used to puncture the seal. The tube should not be used and the pharmacist should be contacted if the seal is missing, punctured, or lifted. Ledaga should be applied immediately or within 30 minutes after removal from the refrigerator. The tube should be returned to the

refrigerator immediately after each use. With clean hands, the tube should be placed back into the original box and the box should be placed in the supplied transparent, sealable, plastic bag for storage in the refrigerator. Ledaga should be applied to completely dry skin at least 4 hours before or 30 minutes after showering or washing. The patient should allow treated areas to dry for 5 to 10 minutes after application before covering with clothing. Occlusive (air- or water-tight) dressings should not be used on areas of the skin where Ledaga was applied. Emollients (moisturisers) or other topical products may be applied to the treated areas 2 hours before or 2 hours after application of Ledaga. Fire, flame, and smoking must be avoided until Ledaga has dried. **Contraindications:** Hypersensitivity to chlormethine or to any of the excipients. **Warnings and precautions for use:** Mucosal or eye exposure: contact with mucous membranes, especially those of the eyes, must be avoided. Patients should be advised if any mucous membrane exposure occurs to irrigate immediately for at least 15 minutes with copious amounts of water and obtain medical care. **Local skin reactions:** patients should be assessed during treatment for skin reactions. **Hypersensitivity:** reactions have been reported in the literature after the use of topical formulations of chlormethine. **Skin cancer:** skin-directed therapies for MF-type CTCL have been associated with secondary skin cancers, although the specific contribution of chlormethine has not been established. Patients should be monitored for development of skin cancers during and after discontinuation of treatment with chlormethine. **Secondary exposure to Ledaga:** direct skin contact with Ledaga should be avoided in individuals other than the patient. **Excipients:** Ledaga contains propylene glycol and butylhydroxytoluene, which may cause skin irritation. **Interactions:** No interaction studies have been performed. **Fertility, pregnancy and lactation:** Ledaga is not recommended in women of childbearing potential not using contraception. Ledaga is not recommended during pregnancy. It is unknown whether chlormethine is excreted in human milk. **Effects on availability to drive and use machines:** Ledaga

has no or negligible influence on the ability to drive or use machines. **Undesirable effects:** Very common ($\geq 1/10$): dermatitis, skin infections, pruritus. Common ($\geq 1/100$ to $< 1/10$): skin ulceration and blistering, skin hyperpigmentation, hypersensitivity. **Overdose:** Management of overdose should consist of washing the exposed area with water. **Packaging quantity and storage conditions:** Ledaga is provided in a white aluminium tube with an inner lacquer and an aluminium seal and a white polypropylene screw cap. Each tube contains 60 g of gel. **Unopened tube:** 3 years in the freezer (-15°C to -25°C). After defrosting: 60 days in the refrigerator ($+2^{\circ}\text{C}$ to $+8^{\circ}\text{C}$). Ledaga should be removed from the refrigerator just prior to application and returned to the refrigerator immediately after each use in its box inside the child-resistant, transparent, sealable, plastic bag. Store and transport frozen (-15°C to -25°C). **Marketing Authorisation Holder and Numbers:** Helsinn Birex Pharmaceuticals Ltd, Damastown Mulhuddart, Dublin 15, Ireland. EU/ 1/16/1171/001. **Prescription conditions:** Medicinal product subject to medical prescription. **Date of first authorisation:** 3 March 2017. Date of last revision of prescribing information: March 2017. Full prescribing information available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002826/WC500223798.pdf

Healthcare professionals are asked to report any suspected adverse reactions according to their national provisions. Adverse reactions should also be reported to Helsinn Birex Pharmaceuticals Ltd. (address as above). Tel: +353 1 822 5404

Chlormethine gel is registered in Europe, USA and Israel.

HELSINN

Mechlorethamine is distributed in USA by HTU under the brand name of VALCHLOR.

For complete information regarding LEDAGA, please see Prescribing Information in force in your Country.

Designed for excellence in ECP



www.therakos.eu

The THERAKOS™ CELLEX™ Photopheresis System is indicated for the administration of photopheresis.

CELLEX™ is the world's only fully integrated and validated ECP system, designed to meet the needs of both you and your patients.¹

ECP: extracorporeal photopheresis.



Mallinckrodt
Pharmaceuticals

¹ Knobler R, et al. J Eur Acad Dermatol Venereol. 2014;28 Suppl 1:1-37.

Current treatment patterns and targeted agents in the management of CTCL

Room: Auditori, Auditorio Axa, Avinguda Diagonal,
547, 08029 Barcelona, Spain

Friday 14th February 2020, 13:15-14:15 CEST

Agenda

Time	Session	Speaker
13:15-13:20	Welcome and introductions	Prof. Pablo Ortiz Romero Hospital Universitario 12 de Octubre, Madrid, Spain
13:20-13:35	Contemporary European treatment patterns and responses in relapsed/refractory CTCL	Prof. Pablo Ortiz Romero
13:35-13:50	Recently approved targeted agents in the management of CTCL	Prof. Julia Scarisbrick Queen Elizabeth Hospital, Birmingham, UK
13:50-14:10	Sharing clinical practice: real-world case studies	Prof. Julia Scarisbrick, Prof. Pablo Ortiz Romero
14:10-14:15	Q&A	Prof. Julia Scarisbrick, Prof. Pablo Ortiz Romero

Ficha técnica disponible en la sala.

CTCL, Cutaneous T-cell lymphoma.

All trademarks are the property of their
respective owners.

©2020 Millennium Pharmaceuticals, Inc., a wholly
owned subsidiary of Takeda Pharmaceutical
Company Limited. All rights reserved.

GON/BRE/19/0048g

Date of Preparation: January 2020





1999

2019

innate pharma

Innate Pharma is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Pioneer in the biology of NK cell, Innate Pharma has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

www.innate-pharma.com

Cutaneous T-cell lymphoma (CTCL) is a rare, serious, and potentially life-threatening form of **non-Hodgkin's lymphoma**.^{1,2}

In the western world, CTCL constitutes ~75–80% of all primary cutaneous lymphomas (PCL).³

CTCL



BEYOND SKIN DEEP

5%

Sézary syndrome (SS) is much rarer making up only approximately 5%.⁴

60%

The most common form of CTCL is **mycosis fungoides (MF)**, accounting for around 60% of cases.⁵

The type of **skin involvement**, as well as the presence of **extracutaneous disease**, are significant negative prognostic factors in this patient population.⁶

REFERENCES

1. National Organization for Rare Disorders: Cutaneous T-Cell Lymphomas. <https://rarediseases.org/rare-diseases/cutaneous-t-cell-lymphomas/> Accessed January 2019. 2. Scarisbrick JJ, Prince M, Vermeer MH, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. *J Clin Oncol*. 2015;33(32):3766–3773. 3. Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M; ESMO Guidelines Working Group. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2013;24 Suppl 6:vi149–154. 4. Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. *Eur J Cancer*. 2017;77:57–74. 5. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. *Blood*. 2019;133(16):1703–1714. 6. Alpdogan O, Kartan S, et al. Systemic therapy of cutaneous T-cell lymphoma (CTCL). *Chin Clin Oncol*. 2019;8(1):10.